Nutritional formulations for promoting healthy gut

A nutritional composition of chondroitin sulfate and betaine strengthens the intestinal barrier in infants, addressing immature gut issues by enhancing immunity and reducing disease risk.

WO2026236033A1PCT designated stage Publication Date: 2026-11-12ABBOTT LAB INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/026061
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-05
Filing Date
2026-04-30
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Newborns, particularly preterm infants, have an immature immune system and intestinal tract, making them susceptible to intestinal barrier breakdown, leading to infections, diarrhea, allergies, and food intolerance.

Method used

A nutritional composition combining chondroitin sulfate and betaine promotes gut health by improving intestinal barrier function and stimulating the growth of the protective mucus layer, protecting against inflammation and stimulating repair.

Benefits of technology

The combination enhances immunity, promotes healthy development of the immune system, reduces the risk of food allergies, and protects against gastrointestinal pathogens, thereby alleviating and preventing gastrointestinal diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2026026061_12112026_PF_FP_ABST
    Figure US2026026061_12112026_PF_FP_ABST
Patent Text Reader

Abstract

Disclosed are methods and compositions, including infant formulas, for promoting a healthy gut and / or a strong intestinal barrier. The compositions include chondroitin, for instance in the form of chondroitin sulfate, and betaine (trimethylglycine). It has presently been found that the combination of chondroitin and betaine synergistically promotes gut health, e.g. by protecting the intestinal barrier against inflammation and / or stimulating repair of the intestinal barrier after inflammation.
Need to check novelty before this filing date? Find Prior Art

Description

Attorney Docket No. 16003WOO1NUTRITIONAL FORMULATIONS FOR PROMOTING HEALTHY GUTCROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims priority to European Patent Application No. 25382451, filed on May 5, 2025, the entirety of which is incorporated herein by reference.FIELD

[0002] The present disclosure relates to a nutritional composition, such as an infant formula, containing chondroitin, optionally in the form of chondroitin sulfate, and betaine. The present disclosure also relates to methods of promoting gut health and / or improving intestinal barrier function, such as in an infant, by administering a nutritional composition containing chondroitin, optionally in the form of chondroitin sulfate, and betaine.BACKGROUND

[0003] During postnatal development, a newborn's intestine experiences a process of maturation that ends with the production of gastrointestinal epithelium that functions as a selective barrier ti.e., gut barrier or intestinal barrier). The gastrointestinal epithelium permits the absorption of nutrients, electrolytes, and water, while preventing exposure to dietary and microbial antigens, including food allergens. Specifically, this barrier limits the passage of antigens to systemic circulation, thereby preventing infection, inflammatory reactions, and other gastrointestinal diseases and disorders that may occur during infancy and later in life. For very young infants, and particularly preterm infants, who have an immature immune system and intestinal tract, breakdown of the intestinal barrier can hinder development and may result in infection, diarrhea, allergies, and food intolerance.SUMMARY

[0004] The present inventors have found that the combination of chondroitin and betaine together synergistically promote gut health, including by improving intestinal barrier function and stimulating growth of the protective mucus layer.Attorney Docket No. 16003WOO1

[0005] The general inventive concepts are directed to compositions and methods utilizing chondroitin, such as in the form of chondroitin sulfate, in combination with betaine to promote gut health and particularly to promote healthy gut function in a formula-fed infant.

[0006] In certain exemplary embodiments, the general inventive concepts relate to a nutritional composition in either reconstitutable powder or liquid form for use in promoting gut health, and in particular infant gut health. When in liquid form, the nutritional composition comprises an effective amount of chondroitin, e.g. chondroitin sulfate, in combination with an effective amount of betaine. The combination of chondroitin and betaine has been found to be useful to promote gut health, including by improving intestinal barrier function and stimulating growth of the protective mucus layer. In doing so, the combination of chondroitin and betaine has also been found to be useful to promote immunity. In some embodiments, the promoting infant gut health and / or improving intestinal barrier function may include protecting the intestinal barrier against inflammation, stimulating repair of the intestinal barrier after inflammation, or a combination thereof. The nutritional composition may in some embodiments be an infant formula.

[0007] In certain exemplary embodiments, the general inventive concepts relate to methods for promoting gut health, and in particular infant gut health, by administering to an individual such as an infant, a nutritional composition that comprises an effective amount of chondroitin, e.g. chondroitin sulfate, in combination with an effective amount of betaine. The methods for promoting infant gut health and / or improving intestinal barrier function may include protecting the intestinal barrier against inflammation, stimulating repair of the intestinal barrier after inflammation, or a combination thereof. In certain exemplary embodiments, the general inventive concepts also relate to methods for improving immunity by administering to an individual such as an infant, a nutritional composition that comprises an effective amount of chondroitin, e.g. chondroitin sulfate, in combination with an effective amount of betaine.

[0008] The promotion of a strong intestinal barrier produces a number of key health benefits, including for instance improving immunity and promoting healthy development of the immune system, promoting nutrient absorption, reducing a risk of developing food allergies, enhancing protection against gastrointestinal pathogens, and the like.Attorney Docket No. 16003WOO1

[0009] In some embodiments, the nutritional compositions, e.g. infant formulas, may be promoting gut health, and in particular infant gut health, by improving intestinal barrier function, for instance by protecting the intestinal barrier against inflammation, stimulating repair of the intestinal barrier after inflammation, or a combination thereof. In such a way, the nutritional compositions, e.g. infant formulas, may be used to alleviate and / or prevent gastrointestinal diseases and / or disorders resulting from poor intestinal barrier function, including for example intestinal hyperpermeability (leaky gut syndrome), which may be particularly important for preterm infants who are subject to an increased risk due to a potentially immature barrier.

[0010] Administration of the nutritional compositions for improving gut health early in life may also reduce the risk of developing associated conditions and diseases of the gastrointestinal tract later in life. Diseases known to be associated with suboptimal gut health include, but are not limited to, irritable bowel syndrome, colitis (e.g., necrotizing enterocolitis, Crohn's disease, ischemic colitis, cryptosporidium enterocolitis, pseudomembranous colitis, cytomegalovirus, ulcerative colitis), inflammatory bowel disease, celiac disease, colic, food intolerance, and food allergies. Thus, in certain exemplary embodiments, the general inventive concepts also contemplate nutritional compositions, e.g. infant formulas, for treating and / or reducing the risk of any of the above.

[0011] Embodiments of the present disclosure are directed to a nutritional composition, e.g. an infant formula, comprising chondroitin, optionally in one or more sulfated forms generally known as chondroitin sulfate, in combination with betaine. In some embodiments, the betaine may comprise, consist essentially of, or consist of betaine anhydrous.

[0012] In some embodiments, the chondroitin or chondroitin sulfate may be present in the nutritional composition, e.g. infant formula, in an amount of at least 0.25 pg per mL (equivalent to mg / L), alternatively at least 0.5 pg per mL, alternatively at least 1 pg per mL, alternatively at least 10 pg per mL, alternatively at least 50 pg per mL, alternatively at least 100 pg per mL, alternatively at least 200 pg per mL, alternatively at least 300 pg per mL, alternatively at least 400 pg per mL, alternatively at least 500 pg per mL, when the infant formula is a liquid. In some embodiments, for instance, the chondroitin or chondroitin sulfate may be present in an amount between about 0.25 pg per mL and about 5000 pg per mL, alternatively between aboutAttorney Docket No. 16003WOO10.25 pg per mL and about 3000 pg per mL, alternatively between about 0.25 pg per mL and about 2000 pg per mL, alternatively between about 0.25 pg per mL and about 1500 pg per mL, alternatively between about 0.25 pg per mL and about 1000 pg per mL, alternatively between about 50 pg per mL and about 5000 pg per mL, alternatively between about 50 pg per mL and about 3000 pg per mL, alternatively between about 50 pg per mL and about 2000 pg per mL, alternatively between about 50 pg per mL and about 1500 pg per mL, alternatively between about 50 pg per mL and about 1000 pg per mL, alternatively between about 300 pg per mL and about 5000 pg per mL, alternatively between about 300 pg per mL and about 3000 pg per mL, alternatively between about 300 pg per mL and about 2000 pg per mL, alternatively between about 300 pg per mL and about 1500 pg per mL, alternatively between about 300 pg per mL and about 1000 pg per mL, alternatively between about 500 pg per mL and about 5000 pg per mL, alternatively between about 500 pg per mL and about 3000 pg per mL, alternatively between about 500 pg per mL and about 2000 pg per mL, alternatively between about 500 pg per mL and about 1500 pg per mL, alternatively between about 500 pg per mL and about 1000 pg per mL of the infant formula when in liquid form.

[0013] In some embodiments the betaine may be present in the nutritional composition, e.g. infant formula, in an amount of at least about 3.5 pg per mL (equivalent to mg / L), alternatively at least about 4 pg per mL, alternatively at least about 5 pg per mL, alternatively at least about 6 pg per mL. In some embodiments, for instance, the betaine may be present in a liquid composition in an amount between about 3.5 pg per mL and about 20 pg per mL, alternatively between about 3.5 pg per mL and about 15 pg per mL, alternatively between about 3.5 pg per mL and about 14 pg per mL, alternatively between about 3.5 pg per mL and about 12 pg per mL, alternatively between about 3.5 pg per mL and about 10 pg per mL, alternatively between about 4 pg per mL and about 20 pg per mL, alternatively between about 4 pg per mL and about 15 pg per mL, alternatively between about 4 pg per mL and about 14 pg per mL, alternatively between about 4 pg per mL and about 12 pg per mL, alternatively between about 4 pg per mL and about 10 pg per mL; alternatively between about 5 pg per mL and about 20 pg per mL, alternatively between about 5 pg per mL and about 15 pg per mL, alternatively between about 5 pg per mL and about 14 pg per mL, alternatively between about 5 pg per mL and about 12 pg per mL, alternatively between about 5 pg per mL and about 10 pg per mL, alternatively between about 6 pg per mL and about 20 pg per mL, alternatively between about 6 pg per mL and about 15 pgAttorney Docket No. 16003WOO1per mL, alternatively between about 6 pg per mL and about 14 pg per mL, alternatively between about 6 pg per mL and about 12 pg per mL, alternatively between about 6 pg per mL and about 10 pg per mL.

[0014] In some embodiments, the chondroitin or chondroitin sulfate may be present in the nutritional composition, e.g. infant formula, in an amount of at least 100 pg per mL, alternatively at least 200 pg per mL, alternatively at least 300 pg per mL, alternatively at least 400 pg per mL, alternatively at least 500 pg per mL, and the betaine may be present in the nutritional composition, e.g. infant formula, in an amount of at least 3.5 pg per mL, alternatively at least 4 pg per mL, alternatively at least 5 pg per mL, alternatively at least 6 pg per mL. For instance, the chondroitin or chondroitin sulfate may be present in the nutritional composition, e.g. infant formula, in an amount between about 300 pg per mL and about 5000 pg per mL, alternatively between about 300 pg per mL and about 3000 pg per mL, alternatively between about 300 pg per mL and about 2000 pg per mL, alternatively between about 300 pg per mL and about 1500 pg per mL, alternatively between about 300 pg per mL and about 1000 pg per mL, alternatively between about 500 pg per mL and about 5000 pg per mL, alternatively between about 500 pg per mL and about 3000 pg per mL, alternatively between about 500 pg per mL and about 2000 pg per mL, alternatively between about 500 pg per mL and about 1500 pg per mL, alternatively between about 500 pg per mL and about 1000 pg per mL, and the betaine may be present in the nutritional composition, e.g. infant formula, in an amount between about 5 pg per mL and about 20 pg per mL, alternatively between about 5 pg per mL and about 15 pg per mL, alternatively between about 5 pg per mL and about 14 pg per mL, alternatively between about 5 pg per mL and about 12 pg per mL, alternatively between about 5 pg per mL and about 10 pg per mL, alternatively between about 6 pg per mL and about 20 pg per mL, alternatively between about 6 pg per mL and about 15 pg per mL, alternatively between about 6 pg per mL and about 14 pg per mL, alternatively between about 6 pg per mL and about 12 pg per mL, alternatively between about 6 pg per mL and about 10 pg per mL. In some embodiments, the chondroitin may be present in amount between about 300 pg per mL and about 2000 pg per mL and the betaine may be present in an amount between about 5 pg per mL and about 15 pg per mL.

[0015] In some embodiments, the nutritional composition, e.g. infant formula, may also contain sources of protein, carbohydrate, and fat. In some embodiments, for instance, the infantAttorney Docket No. 16003WOO1formula may comprise carbohydrate in an amount of from about 40% to about 60% by weight (on a dry weight basis); fat in an amount of from about 20% to about 40% by weight (on a dry weight basis); and protein in an amount of about 10% to about 25% by weight (on a dry weight basis).

[0016] In some embodiments, the nutritional composition, e.g. infant formula, may further comprise one or more human milk oligosaccharides (HMOs). In embodiments of the nutritional composition, e.g. infant formula, containing one or more HMOs, the one or more HMOs may, in some instances, comprise at least one selected from the group of a fucosylated oligosaccharide, a sialylated oligosaccharide, an N-acetylglucosamine oligosaccharide, and any combination thereof. For instance, the one or more HMOs may comprise a combination of at least one fucosylated oligosaccharide, at least one sialylated oligosaccharide, and at least one N-acetylglucosamine oligosaccharide. In some embodiments, the fucosylated oligosaccharide may comprise at least one of 3-fucosyllactose (3-FL) and 2'-fucosyllactose (2'-FL); the sialylated oligosaccharide may comprise at least one of 3’-sialyllactose (3'-SL) and 6' sialyllactose (6’-SL); and the N-acetylglucosamine oligosaccharide may comprise at least one of lacto-N-neotetraose (LNnT), lacto-N-tetraose (LNT).

[0017] In embodiments of the nutritional composition, e.g. infant formula, containing one or more HMOs, the one or more HMOs may, in some instances, comprise at least one selected from the group of 2'-fucosyllactose, 3-fucosyllactose, 3'-sialyllactose, 6'-sialyllactose, and lacto-N-tetraose, and any combination thereof. In some embodiments, for instance, the one or more HMOs may comprise 2'-fucosyllactose, 3-fucosyllactose, 3 '-sialyllactose, 6'-sialyllactose, and lacto-N-tetraose.

[0018] In some embodiments, the nutritional composition, e.g. infant formula, may contain total HMOs in an amount between 0.1 g / L and 10 g / L when the infant formula is a liquid.

[0019] In some embodiments, the nutritional composition, e.g. infant formula, may contain nucleotides. In embodiments of the infant formula containing nucleotides, the one or more nucleotides may comprise at least one selected from the group of adenosine, cytidine, guanosine, uridine, and any combination thereof. In some embodiments, for example, the infant formula may contain all of adenosine, cytidine, guanosine, and uridine. In some embodiments, theAttorney Docket No. 16003WOO1nutritional composition, e.g. infant formula, may contain total nucleotides in an amount between 15 mg / L and about 110 mg / L when the infant formula is a liquid.

[0020] In some embodiments, the nutritional composition, e.g. infant formula, may further comprise a long chain polyunsaturated fatty acid selected from arachidonic acid, docosahexaenoic acid, and a combination thereof.

[0021] In some embodiments, the nutritional composition, e.g. infant formula, may further comprise a carotenoid selected from lutein, lycopene, beta-carotene, and combinations thereof.

[0022] In some embodiments, the nutritional composition, e.g. infant formula, may be a ready-to-drink liquid, also referred to as a ready-to-feed formula. In other embodiments, the nutritional composition, e.g. infant formula, may be in the form of a powder that is configured to be reconstituted into a liquid for feeding, i.e. a reconstitutable powder.

[0023] The combination of chondroitin and betaine in a nutritional composition, e.g. infant formula, may be used to produce any of a variety of benefits. In some embodiments, for instance, the combination of chondroitin and betaine in a nutritional composition, e.g. infant formula, may be used to promote gut health. In some embodiments, for instance, the combination of chondroitin and betaine in a nutritional composition, e.g. infant formula, may be used to strengthen the intestinal barrier, and thereby promote the development of a healthy gastrointestinal system and / or a healthy immune system. In some embodiments, the combination of chondroitin and betaine in a nutritional composition, e.g. infant formula, may be used to protect the intestinal barrier against inflammation, stimulate repair of the intestinal barrier after inflammation, or a combination thereof.BRIEF DESCRIPTION OF THE DRAWINGS

[0024] The general inventive concepts, as well as embodiments and advantages thereof, are described below in greater detail, by way of example, with reference to the drawings in which:

[0025] Figure 1 is a schematic showing the experimental process used in Example 1.

[0026] Figure 2 is a graph showing the results of Example 1, which demonstrates a strong synergistic effect between chondroitin sulfate and betaine on the expression of Glucose-Attorney Docket No. 16003WOO1Regulated Protein 94 (GRP94), a crucial protein for the folding and assembly of proteins in intestinal goblet cells.

[0027] Figure 3 is a graph showing the results of Example 1, which demonstrates a strong synergistic effect between chondroitin sulfate and betaine on the expression of Trefoil Factor 3 (TFF3), which plays an important role in mucosal repair and protection.DETAILED DESCRIPTION

[0028] The compositions and methods described herein utilize chondroitin, e.g. in the form of chondroitin sulfate, in combination with betaine for promoting intestinal, i.e. gut, health as described in greater detail herein. The compositions, including nutritional compositions, described herein include synthetic nutritional compositions, such as infant formulas, that comprise chondroitin, e.g. in the form of chondroitin sulfate, in combination with betaine. These and other features of the compositions and methods, as well as some of the many optional variations and additions, are described in detail hereafter.

[0029] The terms “nutritional formulation” or “nutritional composition” as used herein, are used interchangeably and. unless otherwise specified, refer to synthetic formulas including nutritional liquids, nutritional powders, nutritional solids, nutritional semi-solids, nutritional semi-liquids, nutritional supplements, and any other nutritional food product as known in the art. The nutritional powders may be reconstituted to form a nutritional liquid, all of which comprise one or more of fat, protein and carbohydrate and are suitable for oral consumption by a human and may be used as a sole or supplemental source of nutrition. The terms “nutritional formulation” or “nutritional composition” do not include human breast milk and do not refer to supplemented milk and are generally shelf stable.

[0030] The term “nutritional liquid” as used herein, unless otherwise specified, refers to nutritional compositions in ready-to-drink liquid form, concentrated form, and nutritional liquids made by reconstituting the nutritional powders described herein prior to use.

[0031] The term “nutritional powder” as used herein, unless otherwise specified, refers to nutritional compositions in flowable or scoopable form that can be reconstituted with water orAttorney Docket No. 16003WOO1another aqueous liquid prior to consumption and includes both spray dried and dry mixed / dry blended powders.

[0032] The term “nutritional semi-solid,” as used herein, unless otherwise specified, refers to nutritional compositions that are intermediate in properties, such as rigidity, between solids and liquids. Some semi-solids examples include puddings, gelatins, and doughs.

[0033] The term “nutritional semi-liquid,” as used herein, unless otherwise specified, refers to nutritional compositions that are intermediate in properties, such as flow properties, between liquids and solids. Some semi-liquids examples include thick shakes and liquid gels.

[0034] The terms “fat” and “oil” as used herein, unless otherwise specified, are used interchangeably to refer to lipid materials derived or processed from plants or animals. These terms also include synthetic lipid materials so long as such synthetic materials are suitable for oral administration to humans.

[0035] The term “shelf stable” as used herein, unless otherwise specified, refers to a nutritional product that remains commercially stable after being packaged and then stored at 18-24° C. for at least 3 months, including from about 6 months to about 24 months, and also including from about 12 months to about 18 months.

[0036] The term “individual” as used herein, refers generally to a preterm infant, infant, toddler, child, or adult.

[0037] The term “infant” as used herein, refers generally to individuals up to age 12 months of age, actual or corrected.

[0038] The term “preterm infant” as used herein, refers to those infants born at less than 37 weeks gestation, have a birth weight of less than 2500 gm, or both.

[0039] As used herein, all concentrations expressed as either “pg / liter,” “mg / liter,” “mg / L,” “mcg / L,” “g / L,” etc., refer to ingredient concentrations within the described nutritional compositions as calculated on an as-fed basis (e.g„ reconstituted for consumption in the case of nutritional powders), unless otherwise specified.Attorney Docket No. 16003WOO1

[0040] The term “reconstitute” or various other forms such as “reconstituted” or “reconstituting” all refer to the general act of adding a suitable amount of liquid, typically water, to a form of nutritional formulation that is not in its ready-to-drink liquid form, such as nutritional powder or a concentrated form of a nutritional liquid, thereby making the nutritional composition ready-to-drink.

[0041] The terms “susceptible” and “at risk” as used herein, unless otherwise specified, mean having little resistance to a certain condition or disease relative to the general population, including being genetically predisposed, having a family history of, and / or having symptoms of the condition or disease. The term refers to those having a vulnerability higher than the general population.

[0042] The terms “treating” and “treatment” and “alleviate” and “alleviating” as used herein, unless otherwise specified, includes delaying the onset of a condition, reducing the severity of symptoms of a condition, or eliminating some or all of the symptoms of a condition.

[0043] All percentages, parts and ratios as used herein, are by weight of the total composition, unless otherwise specified. All such weights, as they pertain to listed ingredients, are based on the active level and, therefore, do not include solvents or by-products that may be included in commercially available materials, unless otherwise specified.

[0044] Numerical ranges as used herein are intended to include every number and subset of numbers within that range, whether specifically disclosed or not. Further, these numerical ranges should be construed as providing support for a claim directed to any number or subset of numbers in that range. For example, a disclosure of from 1 to 10 should be construed as supporting a range of from 2 to 8, from 3 to 7, from 5 to 6, from 1 to 9, from 3.6 to 4.6, from 3.5 to 9.9, and so forth.

[0045] All references to singular characteristics or limitations of the general inventive concepts shall include the corresponding plural characteristic or limitation, and vice versa, unless otherwise specified or clearly implied to the contrary by the context in which the reference is made.Attorney Docket No. 16003WOO1

[0046] All combinations of method or process steps as used herein can be performed in any order, unless otherwise specified or clearly implied to the contrary by the context in which the referenced combination is made.

[0047] The chondroitin and betaine can be formulated in suitable compositions and then, in accordance with the methods of the invention, administered to an individual in a form adapted to the chosen route of administration. The formulations include, but are not limited to, those suitable for oral administration. Oral administration, as defined herein, includes any form of administration in which the composition passes through the esophagus of the patient. For example, oral administration includes nasogastric intubation, in which a tube is run from through the nose to the stomach of the patient to administer food or drugs.

[0048] Oral formulations of the compositions disclosed herein include any solid, liquid, or powder formulation suitable for use herein, provided that such a formulation allows for the safe and effective oral delivery of the chondroitin and betaine, and optional nutritive components. In preferred embodiments, the oral formulation is a liquid nutritional composition or reconstitutable powder. Formulations of the present invention suitable for oral administration may be presented as discrete units such as tablets, troches, capsules, lozenges, wafers, or cachets, each containing a predetermined amount of the chondroitin and betaine, as a powder or granules or as a solution or suspension in an aqueous liquor or non-aqueous liquid such as a syrup, an elixir, an emulsion, or a draught.

[0049] The nutritional compositions and methods may comprise, consist of, or consist essentially of the essential elements of the compositions and methods as described herein, as well as any additional or optional element described herein or otherwise useful in oral applications.Chondroitin / Chondroitin Sulfate

[0050] In an aspect of the general inventive concepts, the compositions and methods of the present disclosure include chondroitin, which is most commonly found in a one or more of a variety of sulfated forms (including, for example, GlcA01-3GalNAc4S (Type A), IdoAal-3GalNAc4S (Type B), GlcApi-3GalNAc6S (Type C), GlcA2Spi-3GalNAc6S (Type D). GlcApi-3GalNAc4,6diS (Type E), etc.) which are all generally and collectively known as chondroitinAttorney Docket No. 16003WOO1sulfate. Chondroitin sulfate (CS) is a glycosaminoglycan (GAG) widely present in the extracellular matrix of animal cartilaginous tissues and cell surfaces. It is also the most prominent GAG component of breastmilk (55% of total GAGs), with lower concentrations found in bovine milk (21% of total GAGs). The total chondroitin sulfate concentration of human milk has been reported as 231 mg / L, while the concentration of chondroitin sulfate in fresh bovine milk is 12.9 mg / L. Chondroitin may also be utilized in an unsulfated form.

[0051] The general inventive concepts are based in part on the unexpected synergistic effect between chondroitin and betaine on the functioning of the intestinal barrier. By improving the functioning of the intestinal barrier, the administration of a combination of chondroitin and betaine reduces the chances of developing allergies and / or food intolerances and promotes a healthy immune system. Strengthening / improving the functioning of the intestinal barrier may also generally be considered improving gut health.

[0052] In certain exemplary aspects the nutritional compositions and methods contemplate providing chondroitin or chondroitin sulfate in an amount of at least 0.25 pg per mL (equivalent to mg / L), alternatively at least 0.5 pg per mL, alternatively at least 1 pg per mL, alternatively at least 10 pg per mL, alternatively at least 50 pg per mL, alternatively at least 100 pg per mL, alternatively at least 200 pg per mL, alternatively at least 300 pg per mL, alternatively at least 400 pg per mL, alternatively at least 500 pg per mL, when the infant formula is a liquid. In some embodiments, for instance, the chondroitin or chondroitin sulfate may be present in an amount between about 0.25 pg per mL and about 5000 pg per mL, alternatively between about 0.25 pg per mL and about 3000 pg per mL, alternatively between about 0.25 pg per mL and about 2000 pg per mL, alternatively between about 0.25 pg per mL and about 1500 pg per mL, alternatively between about 0.25 pg per mL and about 1000 pg per mL, alternatively between about 50 pg per mL and about 5000 pg per mL, alternatively between about 50 pg per mL and about 3000 pg per mL, alternatively between about 50 pg per mL and about 2000 pg per mL, alternatively between about 50 pg per mL and about 1500 pg per mL, alternatively between about 50 pg per mL and about 1000 pg per mL, alternatively between about 300 pg per mL and about 5000 pg per mL, alternatively between about 300 pg per mL and about 3000 pg per mL, alternatively between about 300 pg per mL and about 2000 pg per mL, alternatively between about 300 pg per mL and about 1500 pg per mL, alternatively between about 300 pg per mL and aboutAttorney Docket No. 16003WOO11000 pg per mL, alternatively between about 500 pg per mL and about 5000 pg per mL, alternatively between about 500 pg per mL and about 3000 pg per mL, alternatively between about 500 pg per mL and about 2000 pg per mL, alternatively between about 500 pg per mL and about 1500 pg per mL, alternatively between about 500 pg per mL and about 1000 pg per mL of the infant formula when in liquid form.

[0053] Using a specific reconstitution ratio, one can calculate the amount of chondroitin or chondroitin sulfate in a powdered composition, e.g. by weight percentage. As is understood in the art, higher caloric density formulas can be also prepared by using a higher ratio of powder to water or lower caloric density formulas can be prepared by using a lower ratio of powder to water. The ratio of powder to water to produce a formula of a desired caloric density will also depend on the specific composition, e.g. macronutrient distribution, of the formula.

[0054] Using an example reconstitution ratio of about 145 g / L, one can calculate the amount of chondroitin or chondroitin sulfate in a powdered composition, e.g. by weight percentage, that would provide a liquid concentration of chondroitin or chondroitin sulfate in the above ranges. In certain aspects, the composition of the present disclosure, when in reconstitutable powder form, may comprise chondroitin or chondroitin sulfate of from about 0.0002 wt.% to about 3 wt.% based on the total weight of the composition. In certain aspects, the composition of the present disclosure, when in powder form, may comprise chondroitin or chondroitin sulfate between about 0.0002 wt.% and 2 wt.%, alternatively between 0.0002 wt.% and 1.5 wt.%, alternatively between 0.0002 wt.% and 1.0 wt.%, alternatively between 0.0002 wt.% and 0.70 wt.%, alternatively between 0.0007 wt.% and 3 wt.%, alternatively between 0.0007 wt.% and 2 wt.%, alternatively between 0.0007 wt.% and 1.5 wt.%, alternatively between 0.0007 wt.% and 1.0 wt.%, alternatively between 0.0007 wt.% and 0.70 wt.%. alternatively between 0.007 wt.% and 3 wt.%, alternatively between 0.007 wt.% and 2 wt.%, alternatively between 0.007 wt.% and 1.5 wt.%, alternatively between 0.007 wt.% and 1.0 wt.%, alternatively between 0.007 wt.% and 0.70 wt.%, alternatively between 0.03 wt.% and 3 wt.%, alternatively between 0.03 wt.% and 2 wt.%, alternatively between 0.03 wt.% and 1.5 wt.%, alternatively between 0.03 wt.% and 1.0 wt.%, alternatively between 0.03 wt.% and 0.70 wt.%, alternatively between 0.07 wt.% and 3 wt.%, alternatively between 0.07 wt.% and 2 wt.%, alternatively between 0.07 wt.% and 1.5 wt.%, alternatively between 0.07 wt.% and 1.0 wt.%, alternatively between 0.07 wt.% and 0.70 wt.%,Attorney Docket No. 16003WOO1alternatively between 0.20 wt.% and 3 wt.%, alternatively between 0.20 wt.% and 2 wt.%, alternatively between 0.20 wt.% and 1.5 wt.%, alternatively between 0.20 wt.% and 1.0 wt.%, alternatively between 0.20 wt.% and 0.70 wt.%, alternatively between 0.30 wt.% and 3 wt.%, alternatively between 0.30 wt.% and 2 wt.%, alternatively between 0.30 wt.% and 1.5 wt.%, alternatively between 0.30 wt.% and 1.0 wt.%, alternatively between 0.30 wt.% and 0.70 wt.% of the powder, based on the total weight of the nutritional composition.Betaine

[0055] In an aspect of the general inventive concepts, the compositions and methods of the present disclosure include betaine. Betaine, also known as Trimethylglycine (TMG), may be provided in any known form, including for example its natural form of Trimethylglycine Anhydrous (betaine anhydrous). While in general it is contemplated that at least a portion of the betaine may be added to the nutritional composition, e.g. infant formula, in some embodiments a portion of the total amount of betaine in the nutritional composition may be present from inherent sources, such as non-fat dry milk (also known as dry skim milk).

[0056] The general inventive concepts are based in part on the unexpected synergistic effect between betaine and chondroitin on the functioning of the intestinal barrier. By improving the functioning of the intestinal barrier, the administration of a combination of chondroitin and betaine reduces the chances of developing allergies and / or food intolerances and promotes a healthy immune system. Strengthening / improving the functioning of the intestinal barrier may also generally be considered improving gut health.

[0057] In certain exemplary aspects the nutritional compositions and methods contemplate providing betaine in an amount of at least 3.5 pg per mL (equivalent to mg / L) of nutritional composition, alternatively at least 4.0 pg per mL of nutritional composition, alternatively at least 4.5 pg per mL of nutritional composition, alternatively at least 5.0 pg per mL of nutritional composition, alternatively at least 5.5 pg per mL of nutritional composition, alternatively at least 6.0 pg per mL of nutritional composition. This includes, for example, providing betaine in any amount between about 4.0 pg per mL and about 20.0 pg per mL, alternatively any amount between about 4.0 pg per mL and about 14.0 pg per mL, alternatively any among between about 4.0 pg per mL and about 12.0 pg per mL, alternatively any amount between about 4.0 pg per mL and aboutAttorney Docket No. 16003WOO110.0 g per mL, alternatively any amount between about 5.0 pg per mL and about 20.0 pg per mL, alternatively any amount between about 5.0 pg per mL and about 14.0 pg per mL, alternatively any amount between about 5.0 pg per mL and about 12.0 pg per mL, alternatively any amount between about 5.0 pg per mL and about 10.0 pg per mL, alternatively any amount between about 6.0 pg per mL and about 20.0 pg per mL, alternatively any amount between about 6.0 pg per mL and about 14.0 pg per mL, alternatively any amount between about 6.0 pg per mL and about 12.0 pg per mL, alternatively any amount between about 6.0 pg per mL and about 10.0 pg per mL.

[0058] Using a specific reconstitution ratio, one can calculate the amount of betaine in a powdered composition, e.g. by weight percentage. As is understood in the art, higher caloric density formulas can be also prepared by using a higher ratio of powder to water or lower caloric density formulas can be prepared by using a lower ratio of powder to water. The ratio of powder to water to produce a formula of a desired caloric density will also depend on the specific composition, e.g. macronutrient distribution, of the formula.

[0059] Using an example reconstitution ratio of about 145 g / L, one can calculate the amount of betaine in a powdered composition, e.g. by weight percentage, that would provide a liquid concentration of betaine in the above ranges. In certain aspects, the composition of the present disclosure, when in reconstitutable powder form, may comprise betaine of 0.0002 wt.% and 3 wt.% of the powder, alternatively between 0.0002 wt.% and 2 wt.% of the powder, alternatively between 0.0002 wt.% and 1.5 wt.% of the powder, alternatively between 0.0002 wt.% and 1.0 wt.% of the powder, alternatively between 0.0002 wt.% and 0.70 wt.% of the powder, alternatively between 0.0007 wt.% and 3 wt.% of the powder, alternatively between 0.0007 wt.% and 2 wt.% of the powder, alternatively between 0.0007 wt.% and 1.5 wt.% of the powder, alternatively between 0.0007 wt.% and 1.0 wt.% of the powder, alternatively between 0.0007 wt.% and 0.70 wt.% of the powder, alternatively between 0.007 wt.% and 3 wt.% of the powder, alternatively between 0.007 wt.% and 2 wt.% of the powder, alternatively between 0.007 wt.% and 1.5 wt.% of the powder, alternatively between 0.007 wt.% and 1.0 wt.% of the powder, alternatively between 0.007 wt.% and 0.70 wt.% of the powder, alternatively between 0.03 wt.% and 3 wt.% of the powder, alternatively between 0.03 wt.% and 2 wt.% of the powder, alternatively between 0.03 wt.% and 1.5 wt.% of the powder, alternatively between 0.03 wt.% and 1.0 wt.% of the powder, alternatively between 0.03 wt.% and 0.70 wt.% of the powder, alternatively between 0.07 wt.% and 3 wt.% ofAttorney Docket No. 16003WOO1the powder, alternatively between 0.07 wt.% and 2 wt.% of the powder, alternatively between 0.07 wt.% and 1.5 wt.% of the powder, alternatively between 0.07 wt.% and 1.0 wt.% of the powder, alternatively between 0.07 wt.% and 0.70 wt.% of the powder, alternatively between 0.20 wt.% and 3 wt.% of the powder, alternatively between 0.20 wt.% and 2 wt.% of the powder, alternatively between 0.20 wt.% and 1.5 wt.% of the powder, alternatively between 0.20 wt.% and 1.0 wt.% of the powder, alternatively between 0.20 wt.% and 0.70 wt.% of the powder, alternatively between 0.30 wt.% and 3 wt.% of the powder, alternatively between 0.30 wt.% and 2 wt.% of the powder, alternatively between 0.30 wt.% and 1.5 wt.% of the powder, alternatively between 0.30 wt.% and 1.0 wt.% of the powder, alternatively between 0.30 wt.% and 0.70 wt.% of the powder.Human Milk Oligosaccharides (HMOs)

[0060] In some embodiments, the compositions of the present disclosure may further include one or more human milk oligosaccharides (HMOs). In certain aspects, the compositions include a mixture of HMOs comprising at least one neutral HMO and at least one acidic HMO.

[0061] In certain aspects, the compositions of the present disclosure include an HMO or a mixture of HMOs (e.g., a neutral HMO and an acidic HMO). The HMOs may be isolated or enriched from milk(s) secreted by mammals including, but not limited to: human, bovine, ovine, porcine, or caprine species. The HMOs may also be produced via microbial fermentation, enzymatic processes, chemical synthesis, or combinations thereof.

[0062] Suitable HMOs for use in the compositions of the present disclosure may include neutral oligosaccharides, n-acetyl glucosylated oligosaccharides, acidic HMOs, and HMO precursors. For example, specific non-limiting suitable HMOs that may be included in the compositions according to the present disclosure include: 2’-fucosyllactose (2’ -FL), 3-fucosyllactose (3-FL), Difucosyllactose (DFL), 3’-sialyllactose (3’-SL), 6’-sialyllactose (6’-SL), lacto-N-neotetraose (LNnT), and lacto-N-tetraose (LNT).

[0063] Other HMOs that may be included in certain aspects of the compositions of the present disclosure include: N-acetylglucosamine (GlcNAc); L-fucose (L-Fuc); D-fucose (D-Fuc); fucosyl oligosaccharides (z.e., Lacto-N-fucopentaose I; Lacto-N-fucopentaose II; Lacto-N-fucopentaose III; Lacto-N-difucohexaose I; and Lactodifucotetraose); sialyl fucosyl oligosaccharides (z.e., 3'-Attorney Docket No. 16003WOO1Sialyl-3-fucosyllactose; Disialomonofucosyllacto-N-neohexaose; Monofucosylmonosialyllacto-N-octaose (sialyl Lea); Sialyllacto-N-fucohexaose II; Disialyllacto-N-fucopentaose II; Monofucosyldisialyllacto-N-tetraose); and sialyl oligosaccharides (z'.e., 3-Sialyllactosamine; 6'-Sialyllactosamine; Sialyllacto-N-neotetraose c; Monosialyllacto-N-hexaose; Disialyllacto-N-hexaose I; Monosialyllacto-N-neohexaose I; Monosialyllacto-N-neohexaose II; Disialyllacto-N-neohexaose; Disialyllacto-N-tetraose; Disialyllacto-N-hexaose II; Sialyllacto-N-tetraose a; Disialyllacto-N-hexaose I; and Sialyllacto-N-tetraose b). Also useful are variants in which the glucose (Glc at the reducing end is replaced by N-acetylglucosamine (e.g.. 2'-fucosyl-N-acetylglucosamine (2'-FLNac) is such a variant to 2'-fucosyllactose). These HMOs are described more fully in U. S. Patent Application No. 2009 / 0098240, which is herein incorporated by reference in its entirety. Other suitable examples of HMOs that may be included in the compositions according to the present disclosure include lacto-N-fucopentaose V, lacto-N-hexaose, para-lacto-N-hexaose, lacto-N-neohexaose, para-lacto-N-neohexaose, monofucosyllacto-N-hexaose II, isomeric fucosylated lacto-N-hexaose (1), isomeric fucosylated lacto-N-hexaose (3), isomeric fucosylated lacto-N-hexaose (2), difucosyl-para-lacto-N-neohexaose, difucosyl-para-lacto-N-hexaose, difucosyllacto-N-hexaose, lacto-N-neoocataose, para-lacto-N-octanose, iso-lacto-N-octaose, lacto-N-octaose, monofucosyllacto-neoocataose, monofucosyllacto-N-ocataose, difucosyllacto-N-octaose I, difucosyllacto-N-octaose II, difucosyllacto-N-neoocataose II, difucosyllacto-N-neoocataose I, lacto-N-decaose, trifucosyllacto-N-neooctaose, trifucosyllacto-N-octaose, trifucosyl-iso-lacto-N-octaose, lacto-N-difuco-hexaose II, sialyl-lacto-N-tetraose a, sialyl-lacto-N-tetraose b, sialyl-lacto-N-tetraose c, sialyl-fucosyl-lacto-N-tetraose I, sialyl-fucosyl-lacto-N-tetraose II, and disialyl-lacto-N-tetraose, and combinations thereof.

[0064] The HMOs may be present in the composition, when in liquid form (e.g., ready-to-feed form), in total amounts of HMO in the composition (mg of HMO per mL of composition) of at least about about 0.1 g / L, alternatively at least about 0.2 g / L, alternatively at least about 0.5 g / L, alternatively at least about 1.0 g / L, alternatively at least about 1.5 g / L, alternatively at least about 2.0 g / L, alternatively at least about 2.5 g / L. In some embodiments, the nutritional composition may contain total HMOs in an amount of from about 0.1 g / L to about 20 g / L, including about 0.2 g / L to about 10 g / L, about 1 g / L to about 10 mg / mL, about 2 g / L to about 10 g / L, about 2.5 g / L to about 10 g / L, about 0.1 to about 7.5 g / L, about 0.2 g / L to about 7.5 g / L, about 1 g / L to about 7.5Attorney Docket No. 16003WOO1g / L, about 2 g / L to about 7.5 g / L, and about 2.5 g / L to about 7.5 g / L,, about 0.1 to about 5 g / L, about 0.2 g / L to about 5 g / L, about 1 g / L to about 5 g / L, about 2 g / L to about 5 g / L, and about 2.5 g / L to about 5 g / L. The exact amount of HMO in the composition may depend on the specific HMO or HMDs present and the amounts of other components in the composition.

[0065] In certain aspects of the present disclosure, the composition may include an acidic HMO, and a neutral HMO comprising a fucosylated HMO and an N-acetylated HMO. In certain aspects of the present disclosure, the composition comprises a combination of 2’-FL, 3-FL, DFL, 3’-SL, 6’-SL, and LNT. In certain aspects of the present disclosure, the composition (when in ready-to-feed liquid form) may comprise 2 ’-FL in an amount up to 4.15 mg / mL, LNT in an amount up to 2.11 mg / mL, 3-FL in an amount up to 1.17 mg / mL, 3’-SL in an amount up to 0.36 mg / mL, and 6’-SL in an amount up to 0.44 mg / mL.

[0066] In certain aspects, the composition of the present disclosure, when in powder form, may comprise a total amount of HMOs of from about 1 wt.% to about 10 wt.% based on the total weight of the composition. In certain aspects, the composition of the present disclosure, when in powder form, may comprise a total amount of HMOs of from about 1 wt.% to about 8 wt.% based on the total weight of the nutritional composition, including from about 1.5 wt.% to about 7.5 wt.%, including from about 2 wt.% to about 7 wt.%, including from about 2.5 wt.% to about 6.5 wt.%, and also including from about 3 wt.% to about 6 wt.% based on the total weight of the nutritional composition.Nucleotides

[0067] In some embodiments, the compositions of the present disclosure may additionally comprise nucleotides and / or nucleotide precursors selected from the group consisting of nucleosides, purine bases, pyrimidine bases, ribose and deoxyribose. The nucleotide may be in monophosphate, diphosphate, or triphosphate form. The nucleotide may be a ribonucleotide or a deoxyribonucleotide. The nucleotides may be monomeric, dimeric, or polymeric (including RNAAttorney Docket No. 16003WOO1and DNA). The nucleotide may be present in the nutritional composition as a free acid or in the form of a salt, preferably a monosodium salt.

[0068] Suitable nucleotides and / or nucleosides for use in the nutritional compositions include one or more of cytidine 5 '-monophosphate, uridine 5 '-monophosphate, adenosine 5'-monophosphate, guanosine 5'- 1 -monophosphate, and / or inosine 5 '-monophosphate, more preferably cytidine 5 '-monophosphate, uridine 5 '-monophosphate, adenosine 5 '-monophosphate, guanosine 5 '-monophosphate, and inosine 5 '-monophosphate.

[0069] When present, the nutritional composition may include nucleotides in a total amount of about 15 mg / L to about 150 mg / mL, including about 15 mg / L to about 110 mg / L, including about 20 mg / L to about 110 mg / L of the nutritional composition, including about 30 mg / L to about 100 mg / L of the nutritional composition, including about 50 mg / L to about 100 mg / L of the nutritional composition, including about 15 mg / L to about 100 mg / mL, including about 15 mg / L to about 80 mg / mL, including about 30 mg / L to about 90 mg / L, including about 40 mg / L to about 90 mg / mL of the nutritional composition. In order to obtain a concentration within this range when reconstituted with water, the nutritional composition may include nucleotides in an amount of about 0.01 wt. % to about 0.10 wt. % of the nutritional composition when the nutritional composition is a reconstitutable powder.

[0070] In certain exemplary aspects of the present disclosure, the nucleotides may comprise about 40-50% cytidine 5’ monophosphate, about 15-20% uridine 5 '-monophosphate, about 12-18% adenosine 5 '-monophosphate and about 20-25% guanosine 5 '-monophosphate by total weight of nucleotides. In certain exemplary aspects of the present disclosure, the nucleotides may comprise about 43% cytidine 5 '-monophosphate, about 18.5% uridine 5 '-monophosphate, about 16.5% adenosine 5 '-monophosphate and about 22% guanosine 5 '-monophosphate by total weight of nucleotides.

[0071] In an exemplary aspect, the nucleotides may be present in the nutritional compositions in a total amount of about 50 mg / L to about 150 mg / mL or more of the nutritional composition and comprise about 25 to 39 mg / L of cytidine 5 '-monophosphate; 10 to 21 mg / L of uridine 5'-monophosphate; 10 to 15 mg / L of adenosine 5 '-monophosphate; and 12 to 20 mg / L of guanosine 5 '-monophosphate.Attorney Docket No. 16003WOO1

[0072] In an exemplary aspect, the nucleotides may be present in the weight ratio of cytidine 5'-monophosphate: uridine 5 '-monophosphate is from about 1.5:1 to about 2.6:1; of cytidine 5'-monophosphate: adenosine 5 '-monophosphate is from about 2:1 to about 3.9:1; and of cytidine 5'-monophosphate: guanosine 5 '-monophosphate is from about 1.75:1 to about 2.8:1.

[0073] In certain embodiments, the nutritional composition includes a combination of the chondroitin sulfate, HMOs, and nucleotides as described herein such that the composition provides a synergistic benefit to the end user, such as a synergistic benefit in strengthening the intestinal barrier.Macronutrients

[0074] In addition to the specific functional ingredients described herein, the nutritional composition may in many embodiments, such as where the nutritional composition is an infant formula, include one or more ingredients that help satisfy the individual’s nutritional requirements. The optional nutrients can provide up to about 1000 kcal of energy per serving or dose, including from about 25 to about 900 kcal, from about 75 to about 700 kcal, from about 150 to about 500 kcal, from about 350 to about 500 kcal, or from about 200 to about 300 kcal.

[0075] The nutritional compositions may be formulated with sufficient kinds and amounts of nutrients to provide a sole, primary, or supplemental source of nutrition, or to provide a specialized nutritional product for use in individuals afflicted with specific diseases or conditions or with a targeted nutritional benefit as described below.

[0076] The nutritional compositions may be formulated to include at least one of protein, fat. and carbohydrate. In many embodiments, the nutritional compositions will include protein, carbohydrate and fat. Although total concentrations or amounts of the fat, protein, and carbohydrates may vary depending upon the product type (i.e., nutritional formula), product form (i.e., nutritional solid, powder, ready-to-feed liquid, or concentrated liquid) and targeted dietary needs of the intended user, such concentrations or amounts most typically fall within one of the following embodied ranges, inclusive of any other essential fat, protein, and / or carbohydrate ingredients as described herein.Nutritional CompositionsAttorney Docket No. 16003WOO1

[0077] Nutritional compositions, as discussed herein, include at least one of fat, carbohydrate, and protein in addition to the chondroitin and betaine. Infant formulas, which are configured to provide sole source nutrition, will typically contain a combination of fat, carbohydrate, and protein.

[0078] Where present, carbohydrate concentrations most typically will range from about 10% to about 65%, including from about 20% to about 60%, including from about 30% to about 60%, by dry weight of the nutritional composition. Where present, fat concentrations most typically range from about 10% to about 45%, including from about 15% to about 40%, and also including from about 20% to about 40%, by dry weight of the nutritional composition. Where present, protein concentrations most typically range from about 5% to about 30%, including from about 10% to about 30%, and also including from about 15% to about 25%, by dry weight of the nutritional composition. In some embodiments, an infant formula may include from about 40% to about 60% carbohydrates, from about 10% to about 25% protein, and from about 20% to about 40% fat by dry weight of the infant formula.

[0079] The amount of any or all of the carbohydrates, fats, and proteins in any of the nutritional compositions (e.g., infant formula) described herein may also be characterized as a percentage of total calories in the nutritional composition. In some embodiments, the nutritional composition (e.g. infant formula) may contain carbohydrates in an amount of from about 35% to about 50% as a percentage of total calories, protein in an amount of from about 5% to about 20% as a percentage of total calories, and fat in an amount of from about 35% to about 55% as a percentage of total calories.Fat

[0080] The nutritional compositions according to the general inventive concepts may comprise a source or sources of fat. Suitable sources of fat for use herein include any fat or fat source that is suitable for use in an oral nutritional product and is compatible with the essential elements and features of such products. Most typically the fat may be an emulsified fat. In an exemplary embodiment, the fat is derived from short chain fatty acids.

[0081] Non-limiting examples of suitable fats or sources thereof for use in the nutritional products described herein include coconut oil. fractionated coconut oil, soybean oil, corn oil,Attorney Docket No. 16003WOO1olive oil, safflower oil, high oleic safflower oil, oleic acids (EMERSOL 6313 OLEIC ACID, Cognis Oleochemicals, Malaysia), MCT oil (medium chain triglycerides), sunflower oil, high oleic sunflower oil, palm and palm kernel oils, palm olein, canola oil, marine oils, fish oils, fungal oils, algae oils, cottonseed oils, and combinations thereof. Lipid sources of arachidonic acid and docosahexaenoic acid include, but are not limited to, marine oil, egg yolk oil, and fungal or algal oil.

[0082] Numerous commercial sources for these fats are readily available and known to one practicing the art. For example, soy and canola oils are available from Archer Daniels Midland of Decatur, Ill. Com, coconut, palm and palm kernel oils are available from Premier Edible Oils Corporation of Portland, Organ. Fractionated coconut oil is available from Henkel Corporation of LaGrange, Ill. High oleic safflower and high oleic sunflower oils are available from SVO Specialty Products of Eastlake, Ohio. Marine oil is available from Mochida International of Tokyo, Japan. Olive oil is available from Anglia Oils of North Humberside, United Kingdom. Sunflower and cottonseed oils are available from Cargil of Minneapolis, Minn. Safflower oil is available from California Oils Corporation of Richmond, Calif.

[0083] In addition to these food grade oils, structured lipids may be incorporated into the food product if desired. Structured lipids are known in the art. A concise description of structured lipids can be found in INFORM, Vol. 8, No. 10, page 1004; entitled Structured lipids allow fat tailoring (October 1997). Also see U. S. Pat. No. 4,871,768. Structured lipids are predominantly triacylglycerols containing mixtures of medium and long chain fatty acids on the same glycerol nucleus. Structured lipids and their use in enteral formula are also described in U. S. Pat. Nos. 6,194,379 and 6,160,007.

[0084] Optionally, co-3 fatty acids may comprise up to approximately 5% of the oil blend, preferably the co-3 fatty acids largely consist of the longer chain forms, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Dietary oils used in the preparation of the nutritional composition generally contain co-3 fatty acids in the triglyceride form and include, but are not limited to canola, medium chain triglycerides, fish, soybean, soy lecithin, corn, safflower, sunflower, high-oleic sunflower, high-oleic safflower, olive, borage, black currant, evening primrose and flaxseed oil. Optionally, the weight ratio of co-6 fatty acids to co-3 fatty acids in theAttorney Docket No. 16003WOO1lipid blend according to the invention is about 0.1 to 3.0. The daily delivery of co-3 fatty acids should be at least 450 mg and may vary depending on body weight, sex, age and medical condition of the individual. As mentioned, higher levels are desired for adult human consumption: for example, from about 0.5 to 50 gm daily, more preferably from about 2.5 to 5 gm dailyProtein

[0085] In certain exemplary embodiments, the nutritional compositions according to the general inventive concepts include protein. Any protein source that is suitable for use in oral nutritional compositions and is compatible with the essential elements and features of the general inventive concepts may be used.

[0086] Non-limiting examples of suitable proteins or sources thereof for use in the nutritional compositions include hydrolyzed, partially hydrolyzed or non-hydrolyzed proteins or protein sources, which may be derived from any known or otherwise suitable source such as milk (e.g.. casein, whey), animal (e.g., meat, fish), cereal (e.g., rice, com), vegetable (e.g., soy) or combinations thereof. Non-limiting examples of such proteins include milk protein isolates, milk protein concentrates as described herein, casein protein isolates, extensively hydrolyzed casein, whey protein, sodium or calcium caseinates, whole cow milk, partially or completely defatted milk, soy protein isolates, and soy protein concentrates.

[0087] In an exemplary embodiment, the protein source is a hydrolyzed protein, i.e., a protein hydrolysate. In this context, the terms “hydrolyzed protein” or “protein hydrolysates” are used interchangeably herein and include extensively hydrolyzed proteins, wherein the degree of hydrolysis is most often at least about 20%, including from about 20% to about 80%, and also including from about 30% to about 80%, even more preferably from about 40% to about 60%. The degree of hydrolysis is the extent to which peptide bonds are broken by a hydrolysis method. The degree of protein hydrolysis for purposes of characterizing the extensively hydrolyzed protein component of these embodiments is easily determined by one of ordinary skill in the formulation arts by quantifying the amino nitrogen to total nitrogen ratio (AN / TN) of the protein component of the selected liquid formulation. The amino nitrogen component is quantified by USP titration methods for determining amino nitrogen content, while the total nitrogenAttorney Docket No. 16003WOO1component is determined by the Tecator Kjeldahl method, all of which are well known methods to one of ordinary skill in the analytical chemistry art.

[0088] Suitable hydrolyzed proteins include soy protein hydrolysate, casein protein hydrolysate, whey protein hydrolysate, rice protein hydrolysate, potato protein hydrolysate, fish protein hydrolysate, egg albumen hydrolysate, gelatin protein hydrolysate, combinations of animal and vegetable protein hydrolysates, and combinations thereof. Particularly preferred protein hydrolysates include whey protein hydrolysate and hydrolyzed sodium caseinate.

[0089] In some embodiments, the protein source may include at least about 20% (by weight total protein) protein hydrolysate, including from about 30% to 100% (by weight total protein) protein hydrolysate, and including from about 40% to about 80% (by weight total protein) protein hydrolysate, and including about 50% (by weight total protein) protein hydrolysate.Carbohydrate

[0090] In an exemplary embodiment, the nutritional compositions according to the general inventive concepts include carbohydrates that are suitable for use in an oral nutritional composition and are compatible with the essential elements and features of the general inventive concepts.

[0091] Non-limiting examples of suitable carbohydrates or sources thereof for use in the nutritional compositions described herein include maltodextrin, hydrolyzed or modified starch or cornstarch, glucose polymers, corn syrup, com syrup solids, rice-derived carbohydrates, pea-derived carbohydrates, potato-derived carbohydrates, tapioca, sucrose, glucose, fructose, lactose, high fructose com syrup, honey, sugar alcohols (e.g., maltitol, erythritol, sorbitol), artificial sweeteners (e.g., sucralose, acesulfame potassium, stevia) and combinations thereof. A particularly desirable carbohydrate is a low dextrose equivalent (DE) maltodextrin.Long Chain Polyunsaturated Fatty Acids (LCPUFAs)

[0092] The nutritional compositions according to the general inventive concepts may also include Long Chain Polyunsaturated Fatty Acids (LCPUFAs). LCPUFAs are included in the nutritional compositions to provide nutritional support and other benefits to the end user.Attorney Docket No. 16003WOO1

[0093] Exemplary LCPUFAs for use in the nutritional compositions include, for example, OD-3 LCPUFAs and co-6 LCPUFAs. Specific LCPUFAs include docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA), arachidonic acid (ARA), linoleic acid, linolenic acid (alpha linolenic acid) and gamma-linolenic acid derived from oil sources such as plant oils, marine plankton, fungal oils, krill oil and fish oils. In one particular aspect, the LCPUFAs are derived from fish oils such as menhaden, salmon, anchovy, cod. halibut, tuna, or herring oil. Particularly preferred LCPUFAs for use in the nutritional compositions include DHA, ARA, EPA, DPA, and combinations thereof.

[0094] In order to reduce potential side effects of high dosages of LCPUFAs including DHA, ARA, EPA, DPA, in the nutritional compositions, the content of DHA, ARA, EPA, DPA, preferably does not exceed 5% by weight of the total fat content, including below 2% by weight of the total fat content, and including below 1 % by weight of the total fat content in the nutritional composition.

[0095] The LCPUFA may be provided as free fatty acids, in triglyceride form, in diglyceride form, in monoglyceride form, in phospholipid form, in esterified form or as a mixture of one or more of the above, preferably in triglyceride form.

[0096] The nutritional compositions as described herein may comprise total concentrations of ARA, DHA, EPA, and DPA of from about 0.001 g / L to about 1 g / L or more, including from about 0.01 g / L to about 1 g / L, and about 0.1 g / L to about 1 g / L.

[0097] In an exemplary aspect, the nutritional compositions may include a long chain polyunsaturated fatty acid component comprising DHA and ARA in a concentration of from about 0.17 mg / mL to about 0.33 mg / mL, including from about 0.17 mg / mL to about 0.26 mg / mL of ARA and DHA. In an exemplary aspect, the nutritional compositions may include DHA in a concentration of from about 0.025 mg / mL to about 0.130 mg / mL. In another aspect, the nutritional compositions may include ARA in a concentration of from about 0.080 mg / mL to about 0.350 mg / mL. In yet another aspect, the nutritional compositions may include combinations of DHA and ARA such that the ratio of DHA to ARA ranges from about 1:4 to about 1:2.AntioxidantsAttorney Docket No. 16003WOO1

[0098] Additionally, the nutritional compositions may comprise one or more antioxidants.

[0099] Any antioxidants suitable for oral administration may be included for use in the nutritional compositions according to the general inventive concepts, including, for example, vitamin A, vitamin E, vitamin C, retinol, tocopherol, and carotenoids, including lutein, betacarotene, zeaxanthin, and lycopene, and combinations thereof, for example.

[0100] The nutritional composition may comprise at least one carotenoid selected from lutein, lycopene, zeaxanthin, and beta-carotene to provide a total amount of carotenoid of from about 0.001 pg / mL to about 10 pg / mL. More particularly, the nutritional compositions may comprise lutein in an amount of from about 0.001 pg / mL to about 10 pg / mL, including from about 0.001 pg / mL to about 5 pg / mL, including from about 0.001 pg / mL to about 0.0190 pg / mL, including from about 0.001 pg / mL to about 0.0140 pg / mL, and also including from about 0.044 pg / mL to about 5 pg / mL of lutein. The nutritional composition may comprise from about 0.001 pg / mL to about 10 pg / mL, including from about 0.001 pg / mL to about 5 pg / mL, from about 0.001 pg / mL to about 0.0130 pg / mL, including from about 0.001 pg / mL to about 0.0075 pg / mL, and also including from about 0.0185 pg / mL to about 5 pg / mL of lycopene. The nutritional compositions may comprise from about 1 pg / mL to about 10 pg / mL, including from about 1 pg / mL to about 5 pg / mL, including from about 0.001 pg / mL to about 0.025 pg / mL, including from about 0.001 pg / mL to about 0.011 pg / mL, and also including from about 0.034 pg / mL to about 5 pg / mL of beta-carotene. It should be understood that any combination of these amounts of beta-carotene, lutein, zeaxanthin, and lycopene can be included in the nutritional compositions according to the general inventive concepts. Other carotenoids may optionally be included in the nutritional compositions as described herein. Any one or all of the carotenoids included in the nutritional compositions described herein may be from a natural source or artificially synthesized.

[0101] Each of the carotenoids in the selected combinations can be obtained from any known or otherwise suitable material source for use in nutritional compositions, and each can be provided individually, or all together, or in any combination and from any number of sources, including sources such as multivitamin premixes containing other vitamins or minerals in combination with one or more of the carotenoids as described herein. Non-limiting examples of some suitable sources of lutein, lycopene, beta-carotene, or combinations thereof includeAttorney Docket No. 16003WOO1LycoVit® lycopene (available from BASF, Mount Olive, N. J.), Lyc-O-Mato® tomato extract in oil, powder, or bead form (available from LycoRed Corp., Orange, N. J.), beta-carotene, lutein, or lycopene (available from DSM Nutritional Products, Parsippany, N. J.), FloraGLO® lutein (available from Kemin Health, Des Moines, Iowa), Xangold® Natural Lutein Esters (available from Cognis, Cincinnati, Ohio), and Lucarotin® beta-carotene (available from BASF, Mount Olive, N. J.).Other Potential Ingredients

[0102] The nutritional compositions according to the general inventive concepts may further comprise other optional components that may modify the physical, chemical, aesthetic or processing characteristics of the products or serve as additional nutritional components when used in the targeted population. Many such optional ingredients are known or otherwise suitable for use in other nutritional products and may also be used in the compositions herein, provided that such optional ingredients are safe for oral administration and are compatible with the essential and other ingredients in the selected product form.

[0103] Non-limiting examples of such optional ingredients include preservatives, emulsifying agents, buffers, fructooligosaccharides, fiber, galactooligosaccharides, polydextrose, and other prebiotics, probiotics, pharmaceutical actives, anti-inflammatory agents, additional nutrients as described herein, colorants, flavors, thickening agents and stabilizers, emulsifying agents, lubricants, and so forth.

[0104] The nutritional compositions may further comprise a sweetening agent, preferably including at least one sugar alcohol such as maltitol, erythritol, sorbitol, xylitol, mannitol, isolmalt, and lactitol, and also preferably including at least one artificial or high potency sweetener such as acesulfame K, aspartame, sucralose, saccharin, stevia, and tagatose. These sweetening agents, especially as a combination of a sugar alcohol and an artificial sweetener, are especially useful in formulating liquid beverage embodiments according to the general inventive concepts having a desirable favor profile. These sweetener combinations are especially effective in masking undesirable flavors sometimes associated with the addition of vegetable proteins to a liquid beverage. Optional sugar alcohol concentrations in the nutritional product may range from at least 0.01%, including from about 0.1% to about 10%. and also including from about 1% toAttorney Docket No. 16003WOO1about 6%, by weight of the nutritional product. Optional artificial sweetener concentrations may range from about 0.01%, including from about 0.05% to about 5%, also including from about 0.1% to about 1.0%. by weight of the nutritional product.

[0105] The nutritional compositions may further comprise a flowing agent or anti-caking agent to retard clumping or caking of the powder over time and to make a powder embodiment flow easily from its container. Any known flowing or anti-caking agents that are known or otherwise suitable for use in a nutritional powder or product form are suitable for use herein, non-limiting examples of which include tricalcium phosphate, silicates, and combinations thereof. The concentration of the flowing agent or anti-caking agent in the nutritional composition varies depending upon the product form, the other selected ingredients, the desired flow properties, and so forth, but most typically range from about 0.1% to about 4%, including from about 0.5% to about 2%, by weight of the nutritional composition.

[0106] The nutritional compositions may further comprise a stabilizer. Any stabilizer that is known or otherwise suitable for use in a nutritional composition is also suitable for use herein, some non-limiting examples of which include gums such as xanthan gum. The stabilizer may represent from about 0.1% to about 5.0%, including from about 0.5% to about 3%, including from about 0.7% to about 1.5%, by weight of the nutritional composition.

[0107] The nutritional compositions may further comprise any of a variety of other vitamins or related nutrients, non-limiting examples of which include vitamin A, vitamin D, vitamin E, vitamin K, thiamine, riboflavin, pyridoxine, vitamin Bn, niacin, folic acid, pantothenic acid, biotin, vitamin C, choline, inositol, salts and derivatives thereof, and combinations thereof. The food products preferably include, but are not limited to, the following vitamins and minerals: calcium, phosphorus, sodium, chloride, magnesium, manganese, iron, copper, zinc, selenium, iodine, chromium, molybdenum, conditionally essential nutrients m-inositol, carnitine and taurine, and Vitamins A, C, D, E (including natural vitamin E), K and the B complex, and mixtures thereof.

[0108] The nutritional compositions may further comprise any of a variety of other additional minerals, non-limiting examples of which include calcium, phosphorus, magnesium, iron, zinc,Attorney Docket No. 16003WOO1manganese, copper, sodium, potassium, molybdenum, chromium, chloride, and combinations thereof.

[0109] The nutritional compositions also may contain fiber and fiber-like stabilizers. Suitable sources of fiber and / or stabilizers include, but are not limited to, xanthan gum, guar gum, gum arabic, gum ghatti, gum karaya, gum tracacanth, agar, furcellaran, gellan gum, locust bean gum, pectin, low and high methoxy pectin, oat and barley glucans, carrageenans, psyllium, gelatin, microcrystalline cellulose, CMC (sodium carboxymethylcellulose), methylcellulose hydroxypropyl methyl cellulose, hydroxypropyl cellulose, DATEM (diacetyl tartaric acid esters of mono- and diglycerides), dextran, carrageenans, FOS (fructooligosaccharides), and mixtures thereof. Numerous commercial sources of soluble dietary fibers are available. For example, gum arabic, hydrolyzed carboxymethylcellulose, guar gum, pectin and the low and high methoxy pectins are available from TIC Gums, Inc. of Belcamp, Md. The oat and barley glucans are available from Mountain Lake Specialty Ingredients, Inc. of Omaha, Nebr. Psyllium is available from the Meer Corporation of North Bergen, N. I. while the carrageenan is available from FMC Corporation of Philadelphia, Pa.

[0110] In addition to fiber, the nutritional compositions may also contain oligosaccharides that are not naturally found in human milk such as fructooligosaccharides (FOS) or galactooligosaccharides (GOS). These oligosaccharides are rapidly and extensively fermented to short chain fatty acids by anaerobic microorganisms that inhabit the large bowel. These oligosaccharides are preferential energy sources for most Bifidobacterium species, but are not utilized by potentially pathogenic organisms such as Clostridium perfingens, C. difficile, or Eschericia coli.

[0111] The nutritional products may additionally comprise one or more thickeners (z.<?., thickening agents). The addition of thickeners reduces the incidences of paresthesia by inducing the feeling of satiety, which prolongs gastric transit time as discussed above.Product Forms

[0112] The compositions according to the general inventive concepts may be formulated and administered in any known or otherwise suitable oral product form. Any solid, liquid, semi-solid,Attorney Docket No. 16003WOO1and semi-liquid, or powder product form, including combinations or variations thereof, are suitable for use herein, provided that such forms allow for safe and effective oral delivery to the individual of the essential ingredients as also defined herein.

[0113] The compositions may be in any product form comprising the ingredients described herein, and which is safe and effective for oral administration. The compositions may be formulated to include only the ingredients described herein, or may be modified with optional ingredients to form a number of different product forms.

[0114] The compositions according to the general inventive concepts are desirably formulated as dietary product forms, which are defined herein as those embodiments comprising the ingredients according to the general inventive concepts in a product form that then contains at least one of fat, protein, and carbohydrate, and preferably also contains vitamins, minerals, or combinations thereof. The nutritional compositions will comprise at least chondroitin, e.g. in the form of chondroitin sulfate in combination with betaine as described herein; desirably in combination with at least one of protein, fat, carbohydrate, vitamins, and minerals, to produce a nutritional composition.

[0115] Liquid compositions include both concentrated and ready-to-feed liquids. These nutritional liquids are most typically formulated as suspensions or emulsions, although other liquid forms are within the scope of the general inventive concepts. Nutritional compositions in the form of emulsions suitable for use may be aqueous emulsions comprising proteins, fats, and carbohydrates. These emulsions are generally flowable or drinkable liquids at from about 1° C. to about 25° C. and are typically in the form of oil-in-water, water-in-oil, or complex aqueous emulsions, although such emulsions are most typically in the form of oil-in-water emulsions having a continuous aqueous phase and a discontinuous oil phase.

[0116] The nutritional emulsions may be and typically are shelf stable. The nutritional emulsions typically contain up to about 95% by weight of water, including from about 50% to about 95%. also including from about 60% to about 90%, and also including from about 70% to about 85%, of water by weight of the nutritional emulsions. The nutritional emulsions may have a variety of product densities, but most typically may have a density greater than about 1.03 g / mL, including greater than about 1.04 g / mL, including greater than about 1.055 g / mL,Attorney Docket No. 16003WOO1including from about 1.06 g / mL to about 1.12 g / mL, and also including from about 1.085 g / mL to about 1.10 g / mL.

[0117] The nutritional emulsions may have a caloric density tailored to the nutritional needs of the ultimate user, although in most instances the emulsions may comprise generally at least 19 kcal / fl oz (660 kcal / liter), more typically from about 20 kcal / fl oz (675-680 kcal / liter) to about 25 kcal / fl oz (820 kcal / liter), even more typically from about 20 kcal / fl oz (675-680 kcal / liter) to about 24 kcal / fl oz (800-810 kcal / liter). Generally, the 22-24 kcal / fl oz formulas are more commonly used in preterm or low birth weight infants, and the 20-21 kcal / fl oz (675-680 to 700 kcal / liter) formulas are more often used in term infants. In some embodiments, the emulsion may have a caloric density of from about 50-100 kcal / liter to about 660 kcal / liter, including from about 150 kcal / liter to about 500 kcal / liter. In an exemplary embodiment, the emulsion may have a caloric density of 25, or 50, or 75, or 100 kcal / liter.

[0118] The nutritional emulsion may have a pH ranging from about 2.5 to about 8, but are most advantageously in a range of from about 4.5 to about 7.5, including from about 5.5 to about 7.3, including from about 6.2 to about 7.2.

[0119] Although the serving size for the nutritional emulsion can vary depending upon a number of variables, a typical serving size is generally at least about 1 mL, or even at least about 2 mL, or even at least about 5 mL, or even at least about 10 mL, or even at least about 25 mL, including ranges from about 1 mL to about 475 mL, including from about 30 mL to about 360 mL, including from about 60 mL to about 300 mL, and including from about 60 mL to about 240 mL.

[0120] The compositions in the form of solids may be in any solid form but are typically in the form of flowable or substantially flowable particulate compositions, or at least particulate compositions. Particularly suitable nutritional solid product forms include spray dried, agglomerated and / or dry blended powder compositions. The compositions can easily be scooped and measured with a spoon or similar other device, and can easily be reconstituted by the intended user with a suitable aqueous liquid, typically water, to form a nutritional composition for immediate oral or enteral use. In this context, “immediate” use generally means within about 48 hours, most typically within about 24 hours, preferably right after reconstitution.Attorney Docket No. 16003WOO1

[0121] The nutritional powders may be reconstituted with water prior to use to a caloric density tailored to the nutritional needs of the ultimate user, although in most instances the powders are reconstituted with water to form compositions comprising at least 19 kcal / fl oz (660 kcal / liter), more typically from about 20 kcal / fl oz (675-680 kcal / liter) to about 25 kcal / fl oz (820 kcal / liter), even more typically from about 20 kcal / fl oz (675-680 kcal / liter) to about 24 kcal / fl oz (800-810 kcal / liter). Generally, the 22-24 kcal / fl oz formulas are more commonly used in preterm or low birth weight infants, and the 20-21 kcal / fl oz (675-680 to 700 kcal / liter) formulas are more often used in term infants. In some embodiments, the reconstituted powder may have a caloric density of from about 50-100 kcal / liter to about 660 kcal / liter, including from about 150 kcal / liter to about 500 kcal / liter. In an exemplary embodiment, the emulsion may have a caloric density of 25, or 50, or 75, or 100 kcal / liter.

[0122] Compositions, e.g. infant formulas, in the form of a reconstitutable powder may in some embodiments be reconstituted by mixing a measured amount of powder with a measured amount of water to obtain a liquid formula of a desired caloric density. In some embodiments, for instance, a liquid formula having a caloric density of about 20 kcal / fl oz may be obtained by mixing about 8.7 g powder with about 2 fl oz water; a liquid formulation having a caloric density of about 22 kcal / fl oz may be obtained by mixing about 17.4 g powder with about 3.5 fl oz water; a liquid formulation having a caloric density of about 24 kcal / fl oz may be obtained by mixing about 26.2 g powder with about 5 fl oz water; a liquid formulation having a caloric density of about 26 kcal / fl oz may be obtained by mixing about 8.7 g powder with about 1.5 fl oz water; a liquid formulation having a caloric density of about 27 kcal / fl oz may be obtained by mixing about 26.2 g powder with about 4.25 fl oz water; or the like.Methods of Manufacture

[0123] The nutritional compositions according to the general inventive concepts may be prepared by any known or otherwise effective manufacturing technique for preparing the nutritional compositions. Many such techniques are known for any given product form such as nutritional liquids or powders and can easily be applied by one of ordinary skill in the art to the nutritional compositions described herein.Attorney Docket No. 16003WOO1

[0124] The nutritional compositions according to the general inventive concepts can therefore be prepared by any of a variety of known or otherwise effective formulation or manufacturing methods. In one suitable manufacturing process, for example, at least three separate slurries are prepared, including a protein-in-fat (PIF) slurry, a carbohydrate-mineral (CHO-MIN) slurry, and a protein-in- water (PIW) slurry. The PIF slurry is formed by heating and mixing the oil (e.g., canola oil, com oil, etc.) and then adding an emulsifier (e.g., lecithin), fat soluble vitamins, and a portion of the total protein (e.g., milk protein concentrate, etc.) with continued heat and agitation. The CHO-MIN slurry is formed by adding with heated agitation to water: minerals (e.g., potassium citrate, dipotassium phosphate, sodium citrate, etc.), trace and ultra- trace minerals (TM / UTM premix), thickening or suspending agents (e.g., avicel, gellan, and carrageenan). The chondroitin, e.g. in the form of chondroitin sulfate, may be added to the CHO-MIN slurry at this stage or with additional minerals and / or carbohydrates as described in the following step. The resulting CHO-MIN slurry is held for 10 minutes with continued heat and agitation before adding additional minerals (e.g., potassium chloride, magnesium carbonate, potassium iodide, etc.), and / or carbohydrates (e.g., fructooligosaccharide, sucrose, com syrup, etc.). The PIW slurry is then formed by mixing with heat and agitation the remaining protein, if any. Betaine, which is water soluble, may be added, for example, to the CHO-MIN slurry (e.g. as part of the additional minerals and / or carbohydrates) or to the PIW slurry.

[0125] The resulting slurries are then blended together with heated agitation and the pH adjusted to 6.6-7.0, after which the composition is subjected to high-temperature short-time (HTST) processing during which the composition is heat treated, emulsified and homogenized, and then allowed to cool. The water soluble vitamins and ascorbic acid are added, the pH is adjusted to the desired range if necessary, flavors are added, and water is added to achieve the desired total solid level. This emulsion can then be further diluted, heat-treated, and packaged to form a ready-to-feed or concentrated liquid, or it can be heat-treated and subsequently processed and packaged as a reconstitutable powder, e.g., spray dried, dry mixed, agglomerated.

[0126] The nutritional solid, such as a spray dried nutritional powder or dry mixed nutritional powder, may be prepared by any collection of known or otherwise effective techniques, suitable for making and formulating a nutritional powder.Attorney Docket No. 16003WOO1

[0127] For example, when the nutritional powder is a spray dried nutritional powder, the spray drying step may likewise include any spray drying technique that is known for or otherwise suitable for use in the production of nutritional powders. Many different spray drying methods and techniques are known for use in the nutrition field, all of which are suitable for use in the manufacture of the spray dried nutritional powders herein.

[0128] One method of preparing the spray dried nutritional powder comprises forming and homogenizing an aqueous slurry or liquid comprising predigested fat, and optionally protein, carbohydrate, and other sources of fat as described above, and then spray drying the slurry or liquid to produce a spray dried nutritional powder. The method may further comprise the step of spray drying, dry mixing, or otherwise adding additional nutritional ingredients, including any one or more of the ingredients described herein, to the spray dried nutritional powder.

[0129] Other suitable methods for making nutritional compositions are described, for example, in U. S. Pat. No. 6,365,218 (Borschel, et al.), U. S. Patent No. 6,589,576 (Borschel, et al.), U. S. Pat. No. 6,306,908 (Carlson, et al.), U. S. Patent Application No. 20030118703 Al (Nguyen, et al.), which descriptions are incorporated herein by reference to the extent that they are consistent herewith.Methods of Use

[0130] The methods of use according to the general inventive concepts include the oral administration of the compositions that include at least chondroitin, e.g. in the form of chondroitin sulfate, in combination with betaine to improve gut health, particularly in an infant and more particularly in a formula-fed infant. The improvement in gut health may include promoting healthy gut function, e.g. by strengthening the intestinal barrier.

[0131] By strengthening the function of the intestinal barrier, the methods of use according to the general inventive concepts also include the oral administration of the compositions that include at least chondroitin, e.g. in the form of chondroitin sulfate, in combination with betaine to aid in digestion, to reduce the chances of developing allergies and / or food intolerances, to improve immunity and / or promote healthy development of the immune system, and / or to treat or prevent formula intolerance or other gastrointestinal diseases or disorders.Attorney Docket No. 16003WOO1

[0132] The compositions as described herein can be administered to individuals including infants, or may, in certain embodiments, be administered to a specific subclass of individuals that are “in need thereof;” that is, to specific individuals that would particularly benefit by administration of the compositions. For example, a specific individual may be “in need of’ the composition as described herein if they are susceptible to (i.e., have one or more of a genetic predisposition, a family history of, and symptoms of the disease or condition) diseases and conditions that can impair / reduce function in one or more of the areas discussed herein, such as chronic inflammation.

[0133] The individual desirably consumes at least one serving of the composition daily, and in some embodiments, may consume two, three, or even more servings per day. Each serving is desirably administered as a single, undivided dose, although the serving may also be divided into two or more partial or divided servings to be taken at two or more times during the day. The methods according to the general inventive concepts include continuous day after day administration, as well as periodic or limited administration, although continuous day after day administration is generally desirable. The methods according to the general inventive concepts are preferably applied on a daily basis, wherein the daily administration is maintained continuously for at least 3 days, including at least 5 days, including at least 1 month, including at least 6 weeks, including at least 8 weeks, including at least 2 months, including at least 6 months, desirably for at least about 18-24 months, desirably as a long term, continuous, daily, dietary source or supplement.

[0134] The individual may desirably have a daily intake of the composition between about 237 mL (8 ounces) and about 1420 mL (48 ounces). Where the composition is an infant formula, the individual may have a daily intake of the composition that corresponds with a conventional feeding schedule based on the specific age of the individual, such as that shown below.Attorney Docket No. 16003WOO1

[0135] The individual desirably consumes an amount of the nutritional composition that provides (a) a dose of at least about 0.1 g chondroitin or chondroitin sulfate per day, alternatively at least about 0.2 g chondroitin or chondroitin sulfate per day, alternatively at least about 0.3 g chondroitin or chondroitin sulfate per day; such as desirably between about 0.1 g and about 2.0 g chondroitin or chondroitin sulfate per day, alternatively between about 0.1 and about 1.5 g chondroitin or chondroitin sulfate per day, alternatively between about 0.2 g and about 2.0 g chondroitin or chondroitin sulfate per day, alternatively between about 0.2 and about 1.5 g chondroitin or chondroitin sulfate per day, alternatively between about 0.3 g and about 2.0 g chondroitin or chondroitin sulfate per day, alternatively between about 0.3 and about 1.5 g chondroitin or chondroitin sulfate per day, and (b) a dose of at least about 0.8 mg of betaine per day, alternatively at least about 1 mg of betaine per day, alternatively at least about 1.2 mg of betaine per day, alternatively at least about 1.4 mg of betaine per day, such as desirably between about 0.8 mg and about 28 mg of betaine per day, alternatively between about 0.8 mg and about 25 mg of betaine per day, alternatively between about 0.8 mg and about 21 mg of betaine per day, alternatively between about 0.8 mg and about 17 mg of betaine per day, alternatively between about 1 mg and about 28 mg of betaine per day, alternatively between about 1 mg and about 25 mg of betaine per day. alternatively between about 1 mg and about 21 mg of betaine per day, alternatively between about 1.2 mg and about 17 mg of betaine per day, alternatively between about 1.2 mg and about 28 mg of betaine per day, alternatively between about 1.2 mg and about 25 mg of betaine per day, alternatively between about 1.2 mg and about 21 mg of betaine per day, alternatively between about 1.2 mg and about 17 mg of betaine per day.

[0136] In some embodiments, for instance, the individual may consume an amount of the nutritional composition that provides a dose of at least 0.1 g chondroitin or chondroitin sulfate per day. e.g. between 0.1 and 1.5 g chondroitin or chondroitin sulfate per day, and a dose of at least 1 mg of betaine per day, e.g. between 1 and 20 mg of betaine per day.

[0137] Based on the foregoing, because some of the method embodiments according to the general inventive concepts are directed to specific subsets or subclasses of identified individuals (that is, the subset or subclass of individuals “in need” of assistance in addressing one or moreAttorney Docket No. 16003WOO1specific diseases or specific conditions noted herein), not all individuals will fall within the subset or subclass of individuals as described herein for certain diseases or conditions. For example, in certain instances not all infants will specifically fall within the class. Rather, it is individuals which would be considered to have an increased susceptibility over the general class of individuals to one or more of the risk factors described above.Examples

[0138] The following example illustrates exemplary embodiments and / or features of the methods and nutritional compositions according to the general inventive concepts. The example is given solely for the purpose of illustration and are not to be construed as limitations of the general inventive concepts, as many variations thereof are possible without departing from the spirit and scope of the general inventive concepts. Though the example involves in vitro tests, because those in vitro tests involve contacting intestinal cells with chondroitin sulfate, betaine, or both, the concentrations of chondroitin sulfate and / or betaine utilized in the in vitro tests are believed to generally correlate with the concentrations of chondroitin sulfate and / or betaine in a nutritional composition. This is because the concentration of chondroitin sulfate and / or betaine present in an ingested nutritional composition is expected to be generally equivalent to that which comes into contact with the intestinal cells upon digestion of the nutritional composition.

[0139] Goblet cells, which are found in the intestines as well as the respiratory tract and conjunctiva, play an important role in intestinal barrier function, gut health, and immunity.Specifically, goblet cells in the intestine produce and secrete mucins, which forms a protective layer of mucus. This protective layer of mucus regulates antigen passage and creates a barrier against pathogens. Protecting goblet cell function is key to maintaining the intestinal mucus barrier, and subsequently gut health. Due to the key role of goblet cells in the intestinal barrier, they are also important for promoting and maintaining immunity.

[0140] Intestinal inflammation causes a loss of the mucus barrier, leading to an increase in gut permeability. In the following example, therefore, goblet cells are contacted with Tumor Necrosis Factor alpha (TNF-a), a substance produced by the immune system that produces inflammation in the goblet cells. Samples of the goblet cells are also contacted with chondroitin sulfate, betaine, or a combination thereof for a defined test period.Attorney Docket No. 16003WOO1

[0141] At the end of the test period, the goblet cells were tested for Glucose-Regulated Protein 94 (GRP94) and Trefoil Factor 3 (TFF3), each of which is an indicator of goblet cell health, and correspondingly intestinal barrier function, gut health, and immunity. Specifically, GRP94 is crucial for managing the folding and assembly of proteins whereas TFF3 is co-secreted from mucous epithelia together with mucins and can be used as a marker of mucosal functioning / homeostasis.

[0142] Example 1: The experimental design of Example 1 is generally shown in Figure 1.

[0143] The human colorectal cancer cell line LS174T was obtained from American Type Culture Collection (ATCC) and maintained in Eagle's Minimum Essential Medium (EMEM) (ATCC) supplemented with 10% fetal bovine serum, 2 mmol / 1 glutamine plus, 100 units / mL penicillin and 0,1 mg / mL streptomycin (Sigma- Aldrich, St. Louis, MO). Cells were cultured at 37 °C in 5% CO2 as recommended by the manufacturer. They were seeded onto 60 mm plates (eLab, Granada, Spain) at a density of 150,000 cells per plate.

[0144] After 24 hours, 10 ng / mL of Tumor Necrosis Factor alpha (TNF-a) (Sigma-Aldrich, St. Louis, MO), was added to each of the samples except the control group. In addition to the TNF-a, a first sample was provided with 0.25 pg / mL chondroitin sulfate, a second sample was provided with 50 pM betaine, a third sample was provided with a combination of 0.25 pg / mL chondroitin sulfate and 50 pM betaine, and a fourth sample with TNF-a but without additional ingredients as a positive control. The TNF-a along with the chondroitin sulfate, betaine, and / or control was incubated on the goblet cells for 72 hours. After treatment, cells were lysed with RIPA buffer (Sigma-Aldrich, St. Louis, MO), supplemented with phosphatase and protease inhibitors (Sigma-Aldrich, St. Louis, MO). Cells were collected and sonicated. Then, extracts were centrifugated for 10 min at 14.000 rpm. Supernatant were collected and protein concentration was measured in extracts using PIERCE™ BCA Protein Assay Kits (Thermo Fisher Scientific, Massachusetts, USA). Aliquots of the extracts (30 pg) were resolved by SDS-PAGE (Bio-Rad Laboratories, California, USA) and analyzed by immunoblotting using anti-GRP94 (Glucose-Regulated Protein 94) antibodies or anti-TFF3 (Trefoil Factor 3) antibodies (Abeam, Cambridge, UK) and anti-GAPDH antibodies (Santa Cruz Biotechnology, Texas, USA). The results are shown in Figures 2 through 3.Attorney Docket No. 16003WOO1

[0145] As shown in Figure 2, the sample contacted exclusively with TNF-a showed a significant drop in the expression of GRP94 compared to the control, which would be expected given that TNF-a is known to produce inflammation of cells such as the goblet cells used here. The sample that was contacted with chondroitin sulfate in addition to the TNF-a showed no increase in the expression of GRP94 over that of the sample contacted exclusively with the inflammation-producing TNF-a. Similarly, the sample that was contacted with betaine in addition to the TNF-a showed little to no statistical increase in the expression of GRP94 over that of the sample contacted exclusively with the inflammation-producing TNF-a. However, the sample that was contacted with a combination of chondroitin sulfate and betaine showed a significant and unexpected improvement in the expression of GRP94 relative to the sample contacted exclusively with the inflammation-producing TNF-a and, indeed, even showed an increase over the control to which no inflammation-causing substance was applied.

[0146] These results are highly surprising given the lack of effect shown by the chondroitin sulfate and betaine individually in this model, and demonstrates a synergistic ability of the combination of chondroitin sulfate and betaine to promote the expression of GRP94, including in cells that are subjected to inflammatory conditions. These results thus demonstrate that the combination of chondroitin sulfate and betaine is surprisingly effective at stimulating the growth of intestinal goblet cells, including during or after periods of inflammation at which time the regrowth and functioning of those goblet cells may be most critical.

[0147] As shown in Figure 3, the sample contacted exclusively with TNF-a showed a significant drop in the expression of TFF3 compared to the control, which would be expected given that TNF-a is known to produce inflammation of cells such as the goblet cells used here. The sample that was contacted with chondroitin sulfate in addition to the TNF-a showed a small increase of about 19%, in the expression of TFF3 over that of the sample contacted exclusively with the inflammation-producing TNF-a. Similarly, the sample that was contacted with betaine in addition to the TNF-a showed a small increase in the expression of TFF of about 16% over that of the sample contacted exclusively with the inflammation-producing TNF-a. However, the sample that was contacted with a combination of chondroitin sulfate and betaine showed a significant and unexpected improvement of about 52% in the expression of TFF3 relative to theAttorney Docket No. 16003WOO1sample contacted exclusively with the inflammation-producing TNF-a and, indeed, even showed an increase over the control to which no inflammation-causing substance was applied.

[0148] These results are highly surprising given the relatively small effects shown by the chondroitin sulfate and betaine individually in this model, and demonstrate a synergistic ability of the combination of chondroitin sulfate and betaine to promote the expression of TFF3, including in cells that are subjected to inflammatory conditions. These results thus demonstrate that the combination of chondroitin sulfate and betaine is surprisingly effective at stimulating mucosal repair and protection, including during or after periods of inflammation at which time the protection and repair of the mucus layer, which plays a critical role in the functioning of the intestinal barrier and to gut health in general, is of great importance.

[0149] Together, these results demonstrate that chondroitin sulfate and betaine produce a surprising synergistic effect on promoting gut health and maintaining or improving the functioning of the intestinal barrier, which plays a key role in immunity. Further, these results demonstrate that chondroitin sulfate and betaine produce a surprising synergistic effect protecting the intestinal barrier against inflammation, stimulating repair of the intestinal barrier after inflammation, or both.

[0150] Unless otherwise indicated herein, all sub-embodiments and optional embodiments are respective sub-embodiments and optional embodiments to all embodiments described herein. While the present application has been illustrated by the description of embodiments thereof, and while the embodiments have been described in considerable detail, it is not the intention of the applicants to restrict or in any way limit the scope of the appended claims to such detail.Additional advantages and modifications will readily appear to those skilled in the art.Therefore, the application, in its broader aspects, is not limited to the specific details, the representative compositions or formulations, and illustrative examples shown and described. Accordingly, departures may be made from such details without departing from the spirit or scope of the applicant’s general disclosure herein.

Claims

Attorney Docket No. 16003WOO1WHAT TS CLAIMED IS:Composition Claims1. A nutritional composition comprising chondroitin, optionally wherein the chondroitin is in the form of chondroitin sulfate, and betaine.

2. The nutritional composition of any preceding claim, wherein the betaine is provided in the form of betaine anhydrous.

3. The nutritional composition of any preceding claim, wherein the nutritional composition is a liquid and wherein the chondroitin or chondroitin sulfate is present in an amount of at least 0.25 mg / L, optionally at least 0.5 mg / L, optionally at least 1 mg / L, optionally at least 10 mg / L, optionally at least 50 mg / L, optionally at least 100 mg / L, optionally at least 300 mg / L, optionally at least 500 mg / L.

4. The nutritional composition of claim 3, wherein the chondroitin or chondroitin sulfate is present in an amount between about 0.25 mg / L and about 5000 mg / L, optionally between about 0.25 mg / L and about 3000 mg / L, optionally between about 0.25 mg / L and about 2000 mg / L, optionally between about 0.25 mg / L and about 1500 mg / L, optionally between about 0.25 mg / L and about 1000 mg / L, optionally between about 50 mg / L and about 5000 mg / L, optionally between about 50 mg / L and about 3000 mg / L, optionally between about 50 mg / L and about 2000 mg / L, optionally between about 50 mg / L and about 1500 mg / L, optionally between about 50 mg / L and about 1000 mg / L. optionally between about 300 mg / L and about 5000 mg / L, optionally between about 300 mg / L and about 3000 mg / L, optionally between about 300 mg / L and about 2000 mg / L, optionally between about 300 mg / L and about 1500 mg / L, optionally between about 300 mg / L and about mg / L, optionally between about 500 mg / L and about 5000 mg / L, optionally between about 500 mg / L and about 3000 mg / L, optionally between about 500 mg / L and about 2000 mg / L, optionally between about 500 mg / L and about 1500 mg / L, optionally between about 500 mg / L and about 1000 mg / L.Attorney Docket No. 16003WOO15. The nutritional composition of any preceding claim, wherein the nutritional composition is a liquid and wherein the betaine is present in an amount of at least about 3.5 mg / L, optionally at least about 4 mg / L, optionally at least about 5 mg / L, optionally at least about 6 mg / L.

6. The nutritional composition of claim 5, wherein the betaine is present in an amount between about 4 mg / L and about 20 mg / L, optionally between about 4 mg / L and about 15 mg / L, optionally between about 4 mg / L and about 14 mg / L, optionally between about 4 mg / L and about 12 mg / L, optionally between about 4 mg / L and about 10 mg / L, optionally between about 5 mg / L and about 20 mg / L, optionally between about 5 mg / L and about 15 mg / L, optionally between about 5 mg / L and about 14 mg / L, optionally between about 5 mg / L and about 12 mg / L, optionally between about 5 mg / L and about 10 mg / L, optionally between about 6 mg / L and about 20 mg / L, optionally between about 6 mg / L and about 15 mg / L, optionally between about 6 mg / L and about 14 mg / L, optionally between about 6 mg / L and about 12 mg / L, optionally between about 6 mg / L and about 10 mg / L.

7. The nutritional composition of any preceding claim, wherein the chondroitin or chondroitin sulfate is present in an amount of at least 300 mg per L and the betaine is present in an amount of at least 5 mg per L when the nutritional composition is a liquid.

8. The nutritional composition of any preceding claim, wherein the chondroitin or chondroitin sulfate is present in an amount between about 300 mg per L and about 2000 mg per L and the betaine is present in an amount between about 5 mg per L and about 15 mg per L when the nutritional composition is a liquid.

9. The nutritional composition of any one of claims 1-2, wherein the nutritional composition is a reconstitutable powder and the chondroitin or chondroitin sulfate is present in an amount of at least 0.0002 wt.% of the powder, optionally at least 0.0003 wt.% of the powder, optionally at least 0.0007 wt.% of the powder, optionally at least 0.007 wt.% of the powder, optionally at least 0.03 wt.% of the powder, optionally at least 0.07 wt.% of the powder, optionally at least 0.20 wt.% of the powder, optionally at least 0.30 wt.% of the powder.Attorney Docket No. 16003WOO110. The nutritional composition of claim 9, wherein the chondroitin or chondroitin sulfate is present in an amount between 0.0002 wt.% and 3 wt.% of the powder, optionally between 0.0002 wt.% and 2 wt.% of the powder, optionally between 0.0002 wt.% and 1.5 wt.% of the powder, optionally between 0.0002 wt.% and 1.0 wt.% of the powder, optionally between 0.0002 wt.% and 0.70 wt.% of the powder, optionally between 0.0007 wt.% and 3 wt.% of the powder, optionally between 0.0007 wt.% and 2 wt.% of the powder, optionally between 0.0007 wt.% and 1.5 wt.% of the powder, optionally between 0.0007 wt.% and 1.0 wt.% of the powder, optionally between 0.0007 wt.% and 0.70 wt.% of the powder, optionally between 0.007 wt.% and 3 wt.% of the powder, optionally between 0.007 wt.% and 2 wt.% of the powder, optionally between 0.007 wt.% and 1.5 wt.% of the powder, optionally between 0.007 wt.% and 1.0 wt.% of the powder, optionally between 0.007 wt.% and 0.70 wt.% of the powder, optionally between 0.03 wt.% and 3 wt.% of the powder, optionally between 0.03 wt.% and 2 wt.% of the powder, optionally between 0.03 wt.% and 1.5 wt.% of the powder, optionally between 0.03 wt.% and 1.0 wt.% of the powder, optionally between 0.03 wt.% and 0.70 wt.% of the powder, optionally between 0.07 wt.% and 3 wt.% of the powder, optionally between 0.07 wt.% and 2 wt.% of the powder, optionally between 0.07 wt.% and 1.5 wt.% of the powder, optionally between 0.07 wt.% and 1.0 wt.% of the powder, optionally between 0.07 wt.% and 0.70 wt.% of the powder, optionally between 0.20 wt.% and 3 wt.% of the powder, optionally between 0.20 wt.% and 2 wt.% of the powder, optionally between 0.20 wt.% and 1.5 wt.% of the powder, optionally between 0.20 wt.% and 1.0 wt.% of the powder, optionally between 0.20 wt.% and 0.70 wt.% of the powder, optionally between 0.30 wt.% and 3 wt.% of the powder, optionally between 0.30 wt.% and 2 wt.% of the powder, optionally between 0.30 wt.% and 1.5 wt.% of the powder, optionally between 0.30 wt.% and 1.0 wt.% of the powder, optionally between 0.30 wt.% and 0.70 wt.% of the powder.

11. The nutritional composition of any one of claims 1-2 and 9-10, wherein the nutritional composition is a reconstitutable powder and the betaine is present in an amount of at least 0.002 wt.% of the powder, optionally at least 0.003 wt.% of the powder, optionally at least 0.004 wt.% of the powder, optionally at least 0.005 wt.% of the powder.Attorney Docket No. 16003WOO112. The nutritional composition of claim 11, wherein the betaine is present in an amount between 0.002 wt.% and 0.03 wt.% of the powder, optionally between 0.002 wt.% and 0.02 wt.% of the powder, optionally between 0.002 wt% and 0.015 wt.% of the powder, optionally between 0.002 wt.% and 0.01 wt.% of the powder, optionally between 0.003 wt.% and 0.03 wt.% of the powder, optionally between 0.003 wt.% and 0.02 wt.% of the powder, optionally between 0.003 wt% and 0.015 wt.% of the powder, optionally between 0.003 wt.% and 0.01 wt.% of the powder, optionally between 0.004 wt.% and 0.03 wt.% of the powder, optionally between 0.004 wt.% and 0.02 wt.% of the powder, optionally between 0.004 wt% and 0.015 wt.% of the powder, optionally between 0.004 wt.% and 0.01 wt.% of the powder, optionally between 0.005 wt.% and 0.03 wt.% of the powder, optionally between 0.005 wt.% and 0.02 wt.% of the powder, optionally between 0.005 wt% and 0.015 wt.% of the powder, optionally between 0.005 wt.% and 0.01 wt.% of the powder.

13. The nutritional composition of any one of claims 1-2, wherein the nutritional composition is a reconstitutable powder, the chondroitin or chondroitin sulfate is present in an amount of at least 0.03 wt.% of the powder, optionally an amount between 0.03 and 2 wt.% of the powder, and the betaine is present in an amount of at least 0.003 wt.% of the powder, optionally an amount between 0.003 and 0.03 wt.% of the powder.

14. The nutritional composition of any preceding claim, wherein the chondroitin or chondroitin sulfate and the betaine are present in an effective amount to promote gut health.

15. The nutritional composition of any preceding claim, wherein the chondroitin or chondroitin sulfate and the betaine are present in an effective amount to improve intestinal barrier function.

16. The nutritional composition of any preceding claim, wherein the chondroitin or chondroitin sulfate and the betaine are present in an effective amount to improve immunity.Attorney Docket No. 16003WOO117. The nutritional composition of any preceding claim, wherein the chondroitin or chondroitin sulfate and the betaine are present in an effective amount to enhance protection against gastrointestinal pathogens.

18. The nutritional composition of any preceding claim, wherein the chondroitin or chondroitin sulfate and the betaine are present in an effective amount to reduce a risk of food allergy.

19. The nutritional composition of any preceding claim, wherein the chondroitin or chondroitin sulfate and the betaine are present in an effective amount to promote nutrient absorption.

20. The nutritional composition of any preceding claim, wherein the chondroitin or chondroitin sulfate and the betaine are present in an effective amount to alleviate or prevent gastrointestinal diseases or disorders resulting from poor intestinal barrier function, optionally wherein the gastrointestinal diseases or disorders are related to premature birth, optionally wherein the gastrointestinal diseases or disorders include intestinal hyperpermeability (leaky gut syndrome).

21. The nutritional composition of any preceding claim, wherein the nutritional composition is a synthetic nutritional composition, optionally a sole-source synthetic nutritional composition.

22. The nutritional composition of any preceding claim, wherein the nutritional composition is an infant formula.

23. The nutritional composition of any preceding claim, wherein the nutritional composition comprises protein, carbohydrate, and fat.

24. The nutritional composition of claim 23, wherein the nutritional composition comprises carbohydrate in an amount of from about 40% to about 60% by weight (on a dry weight basis);Attorney Docket No. 16003WOO1fat in an amount of from about 20% to about 40% by weight (on a dry weight basis); and protein in an amount of about 10% to about 25% by weight (on a dry weight basis).

25. The nutritional composition of any preceding claim, further comprising one or more human milk oligosaccharides (HMOs).

26. The nutritional composition of claim 25, wherein the one or more human milk oligosaccharides comprises at least one selected from the group of a fucosylated oligosaccharide, a sialylated oligosaccharide, an N-acetylglucosamine oligosaccharide, and any combination thereof.

27. The nutritional composition of claim 26, wherein the one or more human milk oligosaccharides comprises a combination of at least one fucosylated oligosaccharide, at least one sialylated oligosaccharide, and at least one N-acetylglucosamine oligosaccharide.

28. The nutritional composition of any one of claims 26 or 27, wherein the fucosylated oligosaccharide comprises at least one of 3-fucosyllactose (3-FL) and 2'-fucosyllactose (2'-FL); the sialylated oligosaccharide comprises at least one of 3’-sialyllactose (3'-SL) and 6' sialyllactose (6’-SL); and / or the N-acetylglucosamine oligosaccharide comprises at least one of lacto-N-neotetraose (LNnT) and lacto-N-tetraose (LNT).

29. The nutritional composition of claim 25, wherein the one or more human milk oligosaccharides comprises at least one selected from the group of 2'-fucosyllactose, 3-fucosyllactose, 3'-sialyllactose, 6'-sialyllactose, and lacto-N-tetraose, and any combination thereof.

30. The nutritional composition of claim 29, wherein the one or more human milk oligosaccharides comprise 2'-fucosyllactose, 3-fucosyllactose, 3'-sialyllactose, 6'-sialyllactose, and lacto-N-tetraose.Attorney Docket No. 16003WOO131. The nutritional composition of any one of claims 25-30, wherein the nutritional composition contains total HMOs in an amount between 0.1 g / L and 10 g / L when the nutritional composition is a liquid.

32. The nutritional composition of any one of claims 25-31, wherein the nutritional composition is a reconstitutable powder and contains total HMOs in an amount between about 1 wt. % and about 10 wt. % of the powder.

33. The nutritional composition of any preceding claim, wherein the nutritional composition further comprises a long chain polyunsaturated fatty acid selected from arachidonic acid, docosahexaenoic acid, and a combination thereof.

34. The nutritional composition of any preceding claim, wherein the nutritional composition further comprises a carotenoid selected from lutein, lycopene, beta-carotene, and combinations thereof.

35. The nutritional composition of any preceding claim, wherein the nutritional composition is a ready-to-feed liquid infant formula.

36. The nutritional composition of any preceding claim 1-34, wherein the nutritional composition is a reconstitutable powder infant formula.Method Claims37. A method for promoting gut health in an infant, toddler, or child comprising administering a nutritional composition comprising chondroitin, optionally in the form of chondroitin sulfate, and betaine to the infant, toddler, or child.

38. The method of claim 37 wherein the infant, toddler, or child is an infant, optionally a formula-fed infant.Attorney Docket No. 16003WOO139. The method of any one of claims 37-38, wherein the promoting gut health comprises protecting the intestinal barrier against inflammation, stimulating repair of the intestinal barrier after inflammation, or a combination thereof.

40. A method for improving intestinal barrier function in an infant, toddler, or child comprising administering a nutritional composition comprising chondroitin, optionally in the form of chondroitin sulfate, and betaine to the infant, toddler, or child.

41. A method for improving intestinal barrier function in an infant, optionally a formula-fed infant, comprising administering a nutritional comprising chondroitin, optionally in the form of chondroitin sulfate, and betaine to the infant.

42. The method of any one of claims 40-41, wherein the improving intestinal barrier function comprises protecting the intestinal barrier against inflammation, stimulating repair of the intestinal barrier after inflammation, or a combination thereof.

43. A method for promoting immunity in an infant, toddler, or child comprising administering a nutritional composition comprising chondroitin, optionally in the form of chondroitin sulfate, and betaine to the infant, toddler, or child.

44. A method for promoting immunity in an infant, optionally a formula-fed infant, comprising administering a nutritional comprising chondroitin, optionally in the form of chondroitin sulfate, and betaine to the infant.

45. The method of any one of claims 43-44, wherein the promoting immunity comprises protecting the intestinal barrier against inflammation, stimulating repair of the intestinal barrier after inflammation, or a combination thereof.

46. A method for enhancing protection against gastrointestinal pathogens in an infant, toddler, or child comprising administering a nutritional composition comprising chondroitin, optionally in the form of chondroitin sulfate, and betaine to the infant, toddler, or child.Attorney Docket No. 16003WOO147. A method for enhancing protection against gastrointestinal pathogens in an infant, optionally a formula-fed infant, comprising administering a nutritional comprising chondroitin, optionally in the form of chondroitin sulfate, and betaine to the infant.

48. The method of any one of claims 46-47. wherein the enhancing protection against gastrointestinal pathogens comprises protecting the intestinal barrier against inflammation, stimulating repair of the intestinal barrier after inflammation, or a combination thereof.

49. A method for reducing a risk of developing food allergies in an infant, toddler, or child comprising administering a nutritional composition comprising chondroitin, optionally in the form of chondroitin sulfate, and betaine to the infant, toddler, or child.

50. A method for reducing a risk of developing food allergies in an infant, optionally a formula-fed infant, comprising administering a nutritional comprising chondroitin, optionally in the form of chondroitin sulfate, and betaine to the infant.

51. The method of any one of claims 49-50, wherein the reducing a risk of developing food allergies comprises protecting the intestinal barrier against inflammation, stimulating repair of the intestinal barrier after inflammation, or a combination thereof.

52. A method for promoting nutrient absorption in an infant, toddler, or child comprising administering a nutritional composition comprising chondroitin, optionally in the form of chondroitin sulfate, and betaine to the infant, toddler, or child.

53. A method for promoting nutrient absorption in an infant, optionally a formula-fed infant, comprising administering a nutritional comprising chondroitin, optionally in the form of chondroitin sulfate, and betaine to the infant.Attorney Docket No. 16003WOO154. The method of any one of claims 52-53, wherein the promoting nutrient absorption comprises protecting the intestinal barrier against inflammation, stimulating repair of the intestinal banner after inflammation, or a combination thereof.

55. A method for alleviating or preventing gastrointestinal diseases or disorders resulting from poor intestinal barrier function, optionally wherein the gastrointestinal diseases or disorders are related to premature birth, optionally wherein the gastrointestinal diseases or disorders include intestinal hyperpermeability (leaky gut syndrome), in an infant, toddler, or child comprising administering a nutritional composition comprising chondroitin, optionally in the form of chondroitin sulfate, and betaine to the infant, toddler, or child.

56. A method for alleviating or preventing gastrointestinal diseases or disorders resulting from poor intestinal barrier function, optionally wherein the gastrointestinal diseases or disorders are related to premature birth, optionally wherein the gastrointestinal diseases or disorders include intestinal hyperpermeability (leaky gut syndrome), in an infant, optionally a formula-fed infant, comprising administering a nutritional comprising chondroitin, optionally in the form of chondroitin sulfate, and betaine to the infant.

57. The method of any one of claims 55-56, wherein the alleviating or preventing gastrointestinal diseases or disorders resulting from poor intestinal barrier function comprises protecting the intestinal barrier against inflammation, stimulating repair of the intestinal barrier after inflammation, or a combination thereof.

58. The method of any one of claims 37 to 57, wherein the infant, toddler, or child is an infant, toddler, or child in need thereof.

59. The method of any one of claims 37 to 58, wherein the nutritional composition is a synthetic nutritional composition.

60. The method of any one of claims 37 to 59, wherein the nutritional composition is an infant formula.Attorney Docket No. 16003WOO161. The method of any one of claims 37 to 60, wherein the nutritional composition is a ready-to-drink liquid.

62. The method of any one of claims 37 to 60, wherein the nutritional composition is a liquid that is reconstituted from a reconstitutable powder.

63. The method of any one of claims 37 to 62, wherein the betaine is in the form of betaine anhydrous.

64. The method of any one of claims 37 to 63, wherein the nutritional composition is a liquid and wherein the chondroitin or chondroitin sulfate is present in an amount of at least 0.25 mg / L, optionally at least 0.5 mg / L, optionally at least 1 mg / L, optionally at least 10 mg / L, optionally at least 50 mg / L, optionally at least 100 mg / L, optionally at least 300 mg / L, optionally at least 500 mg / L.

65. The method of claim 64, wherein the chondroitin or chondroitin sulfate is present in an amount between about 0.25 mg / L and about 5000 mg / L, optionally between about 0.25 mg / L and about 3000 mg / L, optionally between about 0.25 mg / L and about 2000 mg / L, optionally between about 0.25 mg / L and about 1500 mg / L, optionally between about 0.25 mg / L and about 1000 mg / L, optionally between about 50 mg / L and about 5000 mg / L, optionally between about 50 mg / L and about 3000 mg / L, optionally between about 50 mg / L and about 2000 mg / L, optionally between about 50 mg / L and about 1500 mg / L, optionally between about 50 mg / L and about 1000 mg / L, optionally between about 300 mg / L and about 5000 mg / L, optionally between about 300 mg / L and about 3000 mg / L, optionally between about 300 mg / L and about 2000 mg / L, optionally between about 300 mg / L and about 1500 mg / L, optionally between about 300 mg / L and about mg / L, optionally between about 500 mg / L and about 5000 mg / L, optionally between about 500 mg / L and about 3000 mg / L, optionally between about 500 mg / L and about 2000 mg / L, optionally between about 500 mg / L and about 1500 mg / L, optionally between about 500 mg / L and about 1000 mg / L.Attorney Docket No. 16003WOO166. The method of any one of claims 37 to 65, wherein the nutritional composition is a liquid and wherein the betaine is present in an amount of at least about 3.5 mg / L, optionally at least about 4 mg / L, optionally at least about 5 mg / L, optionally at least about 6 mg / L.

67. The method of claim 66, wherein the betaine is present in an amount between about 4 mg / L and about 20 mg / L, optionally between about 4 mg / L and about 15 mg / L, optionally between about 4 mg / L and about 14 mg / L, optionally between about 4 mg / L and about 12 mg / L, optionally between about 4 mg / L and about 10 mg / L, optionally between about 5 mg / L and about 20 mg / L, optionally between about 5 mg / L and about 15 mg / L, optionally between about 5 mg / L and about 14 mg / L, optionally between about 5 mg / L and about 12 mg / L, optionally between about 5 mg / L and about 10 mg / L, optionally between about 6 mg / L and about 20 mg / L, optionally between about 6 mg / L and about 15 mg / L, optionally between about 6 mg / L and about 14 mg / L, optionally between about 6 mg / L and about 12 mg / L, optionally between about 6 mg / L and about 10 mg / L.

68. The method of any one of claims 37 to 67, wherein the chondroitin or chondroitin sulfate is present in an amount of at least 300 mg per L and the betaine is present in an amount of at least 5 mg per L when the nutritional composition is a liquid.

69. The method of any one of claims 37 to 68, wherein the chondroitin or chondroitin sulfate is present in an amount between about 300 mg per L and about 2000 mg per L and the betaine is present in an amount between about 5 mg per L and about 15 mg per L when the nutritional composition is a liquid.

70. The method of any one of claims 37 to 69, wherein the nutritional composition comprises protein, carbohydrate, and fat.

71. The method of claim 70, wherein the nutritional composition comprises carbohydrate in an amount of from about 40% to about 60% by weight (on a dry weight basis); fat in an amount of from about 20% to about 40% by weight (on a dry weight basis); and protein in an amount of about 10% to about 25% by weight (on a dry weight basis).Attorney Docket No. 16003WOO172. The method of any one of claims 37 to 71, wherein the nutritional composition further comprises one or more human milk oligosaccharides (HMOs).

73. The method of claim 72, wherein the one or more human milk oligosaccharides comprises at least one selected from the group of a fucosylated oligosaccharide, a sialylated oligosaccharide, an N-acetylglucosamine oligosaccharide, and any combination thereof.

74. The method of claim 73, wherein the one or more human milk oligosaccharides comprises a combination of at least one fucosylated oligosaccharide, at least one sialylated oligosaccharide, and at least one N-acetylglucosamine oligosaccharide.

75. The method of any one of claims 73-74, wherein the fucosylated oligosaccharide comprises at least one of 3-fucosyllactose (3-FL) and 2'-fucosyllactose (2'-FL); the sialylated oligosaccharide comprises at least one of 3’-sialyllactose (3'-SL) and 6' sialyllactose (6’-SL); and / or the N-acetylglucosamine oligosaccharide comprises at least one of lacto-N-neotetraose (LNnT) and lacto-N-tetraose (LNT).

76. The method of claim 72, wherein the one or more human milk oligosaccharides comprises at least one selected from the group of 2'-fucosyllactose, 3-fucosyllactose, 3'-sialyllactose, 6’-sialyllactose, and lacto-N-tetraose, and any combination thereof.

77. The method of claim 76, wherein the one or more human milk oligosaccharides comprise 2'-fucosyllactose, 3-fucosyllactose, 3'-sialyllactose, 6'-sialyllactose, and lacto-N-tetraose.

79. The method of any one of claims 72-79, wherein the nutritional composition contains total HMOs in an amount between 0.1 g / L and 10 g / L.

80. The method of any one of claims 37 to 79, wherein the nutritional composition further comprises a long chain polyunsaturated fatty acid selected from arachidonic acid, docosahexaenoic acid, and a combination thereof.Attorney Docket No. 16003WOO181. The method of any one of claims 37 to 80, wherein the nutritional composition further comprises a carotenoid selected from lutein, lycopene, beta-carotene, and combinations thereof.

82. The method of any one of claims 37 to 81, wherein the nutritional composition is administered in an amount between about 237 mL (8 ounces) and about 1420 mL (48 ounces) per day.

83. The method of any one of claims 37 to 82, wherein the nutritional composition is administered in an amount that provides the infant, toddler, or child with at least about 0.1 g chondroitin or chondroitin sulfate per day, alternatively at least about 0.2 g chondroitin or chondroitin sulfate per day, alternatively at least about 0.3 g chondroitin or chondroitin sulfate per day; alternatively between about 0.1 g and about 2.0 g chondroitin or chondroitin sulfate per day. alternatively between about 0.1 and about 1.5 g chondroitin or chondroitin sulfate per day, alternatively between about 0.2 g and about 2.0 g chondroitin or chondroitin sulfate per day, alternatively between about 0.2 and about 1.5 g chondroitin or chondroitin sulfate per day, alternatively between about 0.3 g and about 2.0 g chondroitin or chondroitin sulfate per day, alternatively between about 0.3 and about 1.5 g chondroitin or chondroitin sulfate per day.

84. The method of any one of claims 37 to 83, wherein the nutritional composition is administered in an amount that provides the infant, toddler, or child with at least about 0.8 mg of betaine per day, alternatively at least about 1 mg of betaine per day, alternatively at least about 1.2 mg of betaine per day, alternatively at least about 1.4 mg of betaine per day, alternatively between about 0.8 mg and about 28 mg of betaine per day, alternatively between about 0.8 mg and about 25 mg of betaine per day, alternatively between about 0.8 mg and about 21 mg of betaine per day, alternatively between about 0.8 mg and about 17 mg of betaine per day, alternatively between about 1 mg and about 28 mg of betaine per day, alternatively between about 1 mg and about 25 mg of betaine per day, alternatively between about 1 mg and about 21 mg of betaine per day, alternatively between about 1.2 mg and about 17 mg of betaine per day, alternatively between about 1.2 mg and about 28 mg of betaine per day. alternatively between about 1.2 mg and about 25 mg of betaine per day, alternatively between about 1.2 mg and aboutAttorney Docket No. 16003WOO121 mg of betaine per day, alternatively between about 1.2 mg and about 17 mg of betaine per day.

85. The method of any preceding claim, wherein the nutritional composition is administered in an amount that provides the infant, toddler, or child with at least 0.1 g chondroitin or chondroitin sulfate per day, optionally between 0.1 and 1.5 g chondroitin or chondroitin sulfate per day, and at least 1 mg of betaine per day, optionally between 1 and 20 mg of betaine per day.Therapeutic Use Claims86. Chondroitin, optionally in the form of chondroitin sulfate, and betaine for use in promoting gut health in an infant, toddler, or child, optionally an infant, optionally wherein the infant is a formula-fed infant.

87. Chondroitin and betaine for use according to claim 86, wherein the promoting gut health comprises protecting the intestinal barrier against inflammation, stimulating repair of the intestinal banner after inflammation, or a combination thereof.

88. Chondroitin and betaine for use according to any one of claims 86-87, wherein the chondroitin and the betaine are administered in an effective amount to promote gut health.

89. Chondroitin, optionally in the form of chondroitin sulfate, and betaine for use in improving intestinal barrier function in an infant, toddler, or child, optionally an infant, optionally wherein the infant is a formula-fed infant.

90. Chondroitin and betaine for use according to claim 89, wherein the improving intestinal barrier function comprises protecting the intestinal barrier against inflammation, stimulating repair of the intestinal barrier after inflammation, or a combination thereof.Attorney Docket No. 16003WOO191. Chondroitin and betaine for use according to any one of claims 86-87, wherein the chondroitin and the betaine are administered in an effective amount to improve intestinal barrier function.

92. Chondroitin, optionally in the form of chondroitin sulfate, and betaine for use in promoting immunity in an infant, toddler, or child, optionally an infant, optionally wherein the infant is a formula-fed infant.

93. Chondroitin and betaine for use according to claim 92, wherein the promoting immunity comprises protecting the intestinal barrier against inflammation, stimulating repair of the intestinal bander after inflammation, or a combination thereof.

94. Chondroitin and betaine for use according to any one of claims 92-93, wherein the chondroitin and the betaine are administered in an effective amount to promote immunity.

95. Chondroitin, optionally in the form of chondroitin sulfate, and betaine for use in enhancing protection against gastrointestinal pathogens in an infant, toddler, or child, optionally an infant, optionally wherein the infant is a formula-fed infant.

96. Chondroitin and betaine for use according to claim 95, wherein the enhancing protection against gastrointestinal pathogens comprises protecting the intestinal barrier against inflammation, stimulating repair of the intestinal barrier after inflammation, or a combination thereof.

97. Chondroitin and betaine for use according to any one of claims 95-96, wherein the chondroitin and the betaine are administerd in an effective amount to enhance protection against gastrointestinal pathogens.

98. Chondroitin, optionally in the form of chondroitin sulfate, and betaine for use in reducing a risk of developing food allergy in an infant, toddler, or child, optionally an infant, optionally wherein the infant is a formula-fed infant.Attorney Docket No. 16003WOO199. Chondroitin and betaine for use according to claim 98, wherein the reducing a risk of developing food allergy comprises protecting the intestinal barrier against inflammation, stimulating repair of the intestinal barrier after inflammation, or a combination thereof.

100. Chondroitin and betaine for use according to any one of claims 98-99, wherein the chondroitin and the betaine are administered in an effective amount to reduce a risk of developing food allergy.

101. Chondroitin, optionally in the form of chondroitin sulfate, and betaine for use in promoting nutrient absorption in an infant, toddler, or child, optionally an infant, optionally wherein the infant is a formula-fed infant.

102. Chondroitin and betaine for use according to claim 101, wherein the promoting nutrient absorption comprises protecting the intestinal barrier against inflammation, stimulating repair of the intestinal barrier after inflammation, or a combination thereof.

103. Chondroitin and betaine for use according to any one of claims 101-102, wherein the chondroitin and the betaine are administered in an effective amount to promote nutrient absorption.

104. Chondroitin, optionally in the form of chondroitin sulfate, and betaine for use in alleviating or preventing gastrointestinal diseases or disorders resulting from poor intestinal barrier function, optionally wherein the gastrointestinal diseases or disorders are related to premature birth, optionally wherein the gastrointestinal diseases or disorders include intestinal hyperpermeability (leaky gut syndrome), in an infant, toddler, or child, optionally an infant, optionally wherein the infant is a formula-fed infant.

105. Chondroitin and betaine for use according to claim 104, wherein the alleviating or preventing gastrointestinal diseases or disorders resulting from poor intestinal barrier functionAttorney Docket No. 16003WOO1comprises protecting the intestinal barrier against inflammation, stimulating repair of the intestinal barrier after inflammation, or a combination thereof.

106. Chondroitin and betaine for use according to any one of claims 104-105, wherein the chondroitin and the betaine are administered in an effective amount to alleviate or prevent gastrointestinal diseases or disorders resulting from poor intestinal barrier function.

107. Chondroitin and betaine for use according to any one of claims 86 to 106, wherein the betaine is provided in the form of betaine anhydrous.

108. Chondroitin and betaine for use according to any one of claims 86 to 107, wherein the chondroitin and the betaine are present in the form of a nutritional composition which is a liquid, and in which the chondroitin is present in the nutritional composition in an amount of at least 0.25 mg / L, optionally at least 0.5 mg / L, optionally at least 1 mg / L, optionally at least 10 mg / L, optionally at least 50 mg / L, optionally at least 100 mg / L, optionally at least 300 mg / L, optionally at least 500 mg / L.

109. Chondroitin and betaine for use according to claim 108, wherein the chondroitin or chondroitin sulfate is present in the nutritional composition in an amount between about 0.25 mg / L and about 5000 mg / L, optionally between about 0.25 mg / L and about 3000 mg / L, optionally between about 0.25 mg / L and about 2000 mg / L, optionally between about 0.25 mg / L and about 1500 mg / L, optionally between about 0.25 mg / L and about 1000 mg / L, optionally between about 50 mg / L and about 5000 mg / L, optionally between about 50 mg / L and about 3000 mg / L, optionally between about 50 mg / L and about 2000 mg / L, optionally between about 50 mg / L and about 1500 mg / L, optionally between about 50 mg / L and about 1000 mg / L, optionally between about 300 mg / L and about 5000 mg / L, optionally between about 300 mg / L and about 3000 mg / L, optionally between about 300 mg / L and about 2000 mg / L, optionally between about 300 mg / L and about 1500 mg / L, optionally between about 300 mg / L and about mg / L, optionally between about 500 mg / L and about 5000 mg / L, optionally between about 500 mg / L and about 3000 mg / L, optionally between about 500 mg / L and about 2000 mg / L, optionally between about 500 mg / L and about 1500 mg / L, optionally between about 500 mg / L and about 1000 mg / L.Attorney Docket No. 16003WOO1110. Chondroitin and betaine for use according to any one of claims 86 to 109, wherein the chondroitin and the betaine are present in the form of a nutritional composition which is a liquid, and in which the betaine is present in the nutritional composition in an amount of at least about 3.5 mg / L. optionally at least about 4 mg / L, optionally at least about 5 mg / L, optionally at least about 6 mg / L.

111. Chondroitin and betaine for use according to claim 110, wherein the betaine is present in the nutritional composition in an amount between about 4 mg / L and about 20 mg / L, optionally between about 4 mg / L and about 15 mg / L, optionally between about 4 mg / L and about 14 mg / L, optionally between about 4 mg / L and about 12 mg / L, optionally between about 4 mg / L and about 10 mg / L, optionally between about 5 mg / L and about 20 mg / L, optionally between about 5 mg / L and about 15 mg / L, optionally between about 5 mg / L and about 14 mg / L, optionally between about 5 mg / L and about 12 mg / L, optionally between about 5 mg / L and about 10 mg / L, optionally between about 6 mg / L and about 20 mg / L, optionally between about 6 mg / L and about 15 mg / L, optionally between about 6 mg / L and about 14 mg / L, optionally between about 6 mg / L and about 12 mg / L, optionally between about 6 mg / L and about 10 mg / L112. Chondroitin and betaine for use according to any one of claims 86 to 111, wherein the chondroitin or chondroitin sulfate is present in an amount of at least 300 mg per L and the betaine is present in an amount of at least 5 mg per L when the nutritional composition is a liquid.

113. Chondroitin and betaine for use according to any one of claims 86 to 112, wherein the chondroitin or chondroitin sulfate is present in an amount between about 300 mg per L and about 2000 mg per L and the betaine is present in an amount between about 5 mg per L and about 15 mg per L when the nutritional composition is a liquid.

114. Chondroitin and betaine for use according to any one of claims 86 to 113, wherein the chondroitin and the betaine are present in the form of a composition which is a ready-to-feed liquid infant formula.Attorney Docket No. 16003WOO1115. Chondroitin and betaine for use according to any one of claims 86 to 114, wherein the chondroitin and the betaine are present in the form of a reconstitutable powder infant formula, to which water is added to produce a liquid.

116. Chondroitin and betaine for use according to any one of claims 86 to 115, wherein the chondroitin and the betaine are present in the form of a composition which is a powder, and in which the chondroitin is present in an amount of at least 0.0002 wt.% of the powder, optionally at least 0.0003 wt.% of the powder, optionally at least 0.0007 wt.% of the powder, optionally at least 0.007 wt.% of the powder, optionally at least 0.03 wt.% of the powder, optionally at least 0.07 wt.% of the powder, optionally at least 0.20 wt.% of the powder, optionally at least 0.30 wt.% of the powder.

117. Chondroitin and betaine for use according to claim 116, wherein the chondroitin or chondroitin sulfate is present in an amount between 0.0002 wt.% and 3 wt.% of the powder, optionally between 0.0002 wt.% and 2 wt.% of the powder, optionally between 0.0002 wt.% and 1.5 wt.% of the powder, optionally between 0.0002 wt.% and 1.0 wt.% of the powder, optionally between 0.0002 wt.% and 0.70 wt.% of the powder, optionally between 0.0007 wt.% and 3 wt.% of the powder, optionally between 0.0007 wt.% and 2 wt.% of the powder, optionally between 0.0007 wt.% and 1.5 wt.% of the powder, optionally between 0.0007 wt.% and 1.0 wt.% of the powder, optionally between 0.0007 wt.% and 0.70 wt.% of the powder, optionally between 0.007 wt.% and 3 wt.% of the powder, optionally between 0.007 wt.% and 2 wt.% of the powder, optionally between 0.007 wt.% and 1.5 wt.% of the powder, optionally between 0.007 wt.% and 1.0 wt.% of the powder, optionally between 0.007 wt.% and 0.70 wt.% of the powder, optionally between 0.03 wt.% and 3 wt.% of the powder, optionally between 0.03 wt.% and 2 wt.% of the powder, optionally between 0.03 wt.% and 1.5 wt.% of the powder, optionally between 0.03 wt.% and 1.0 wt.% of the powder, optionally between 0.03 wt.% and 0.70 wt.% of the powder, optionally between 0.07 wt.% and 3 wt.% of the powder, optionally between 0.07 wt.% and 2 wt.% of the powder, optionally between 0.07 wt.% and 1.5 wt.% of the powder, optionally between 0.07 wt.% and 1.0 wt.% of the powder, optionally between 0.07 wt.% and 0.70 wt.% of the powder, optionally between 0.20 wt.% and 3 wt.% of the powder, optionally between 0.20Attorney Docket No. 16003WOO1wt.% and 2 wt.% of the powder, optionally between 0.20 wt.% and 1.5 wt.% of the powder, optionally between 0.20 wt.% and 1.0 wt.% of the powder, optionally between 0.20 wt.% and 0.70 wt.% of the powder, optionally between 0.30 wt.% and 3 wt.% of the powder, optionally between 0.30 wt.% and 2 wt.% of the powder, optionally between 0.30 wt.% and 1.5 wt.% of the powder, optionally between 0.30 wt.% and 1.0 wt.% of the powder, optionally between 0.30 wt.% and 0.70 wt.% of the powder.

118. Chondroitin and betaine for use according to any one of claims 86 to 117, wherein the chondroitin and the betaine are present in the form of a composition which is a powder, and in which the betaine is present in an amount of at least 0.002 wt.% of the powder, optionally at least 0.003 wt.% of the powder, optionally at least 0.004 wt.% of the powder, optionally at least 0.005 wt.% of the powder.

119. Chondroitin and betaine for use according to claim 118, wherein the betaine is present in an amount between 0.002 wt.% and 0.03 wt.% of the powder, optionally between 0.002 wt.% and 0.02 wt.% of the powder, optionally between 0.002 wt% and 0.015 wt.% of the powder, optionally between 0.002 wt.% and 0.01 wt.% of the powder, optionally between 0.003 wt.% and 0.03 wt.% of the powder, optionally between 0.003 wt.% and 0.02 wt.% of the powder, optionally between 0.003 wt% and 0.015 wt.% of the powder, optionally between 0.003 wt.% and 0.01 wt.% of the powder, optionally between 0.004 wt.% and 0.03 wt.% of the powder, optionally between 0.004 wt.% and 0.02 wt.% of the powder, optionally between 0.004 wt% and 0.015 wt.% of the powder, optionally between 0.004 wt.% and 0.01 wt.% of the powder, optionally between 0.005 wt.% and 0.03 wt.% of the powder, optionally between 0.005 wt.% and 0.02 wt.% of the powder, optionally between 0.005 wt% and 0.015 wt.% of the powder, optionally between 0.005 wt.% and 0.01 wt.% of the powder.

120. Chondroitin and betaine for use according to any one of claims 86 to 119, wherein the chondroitin and the betaine are present in the form of a composition which is a powder, the chondroitin or chondroitin sulfate is present in an amount of at least 0.03 wt.% of the powder, optionally an amount between 0.03 and 2 wt.% of the powder, and the betaine is present in anAttorney Docket No. 16003WOO1amount of at least 0.003 wt.% of the powder, optionally an amount between 0.003 and 0.03 wt.% of the powder.

121. Chondroitin and betaine for use according to any one of claims 86 to 120, wherein the chondroitin and betaine are present in a synthetic nutritional composition.

122. Chondroitin and betaine for use according to claim 121, wherein the synthetic nutritional composition is an infant formula.

123. Chondroitin and betaine for use according to any one of claims 121-122, wherein the composition comprises protein, carbohydrate, and fat.

124. Chondroitin and betaine for use according to claim 123, wherein the composition comprises carbohydrate in an amount of from about 40% to about 60% by weight (on a dry weight basis); fat in an amount of from about 20% to about 40% by weight (on a dry weight basis); and protein in an amount of about 10% to about 25% by weight (on a dry weight basis).

125. Chondroitin and betaine for use according to any one of claims 121 to 124, wherein the composition further comprises one or more human milk oligosaccharides (HMOs).

126. Chondroitin and betaine for use according to claim 125, wherein the one or more human milk oligosaccharides comprises at least one selected from the group of a fucosylated oligosaccharide, a sialylated oligosaccharide, an N-acetylglucosamine oligosaccharide, and any combination thereof.

127. Chondroitin and betaine for use according to claim 126, wherein the one or more human milk oligosaccharides comprises a combination of at least one fucosylated oligosaccharide, at least one sialylated oligosaccharide, and at least one N-acetylglucosamine oligosaccharide.

128. Chondroitin and betaine for use according to any one of claims 126-127, wherein the fucosylated oligosaccharide comprises at least one of 3-fucosyllactose (3-FL) and 2'-Attorney Docket No. 16003WOO1fucosyllactose (2'-FL); the sialylated oligosaccharide comprises at least one of 3’-sialyllactose (3'-SL) and 6' sialyllactose (6’-SL); and / or the N-acetylglucosamine oligosaccharide comprises at least one of lacto-N-neotetraose (LNnT), lacto-N-tetraose (LNT).

129. Chondroitin and betaine for use according to claim 125, wherein the one or more human milk oligosaccharides comprises at least one selected from the group of 2'-fucosyllactose. 3-fucosyllactose, 3'-sialyllactose, 6'-sialyllactose, and lacto-N-tetraose, and any combination thereof.

130. Chondroitin and betaine for use according to claim 129, wherein the one or more human milk oligosaccharides comprise 2'-fucosyllactose. 3-fucosyllactose, 3'-sialyllactose, 6'-sialyllactose, and lacto-N-tetraose.

131. Chondroitin and betaine for use according to any one of claims 125-130, wherein the composition contains total HMOs in an amount between 0.1 g / L and 10 g / L when the composition is a liquid.

132. Chondroitin and betaine for use according to any one of claims 125-130, wherein the composition is a reconstitutable powder and contains total HMOs in an amount between about 1 wt. % and about 10 wt. % of the powder.

133. Chondroitin and betaine for use according to any one of claims 121 to 132, wherein the composition further comprises a long chain polyunsaturated fatty acid selected from arachidonic acid, docosahexaenoic acid, and a combination thereof.

134. Chondroitin and betaine for use according to any one of claims 121 to 133, wherein the composition further comprises a carotenoid selected from lutein, lycopene, beta-carotene, and combinations thereof.Attorney Docket No. 16003WOO1135. Chondroitin and betaine for use according to any one of claims 121 to 134, wherein the nutritional composition is administered to the infant, toddler, or child in an amount between about 237 mL (8 ounces) and about 1420 mL (48 ounces) per day.

136. Chondroitin and betaine for use according to any one of claims 86 to 135, wherein the chondroitin is administered in an amount of at least about 0.1 g chondroitin or chondroitin sulfate per day, alternatively at least about 0.2 g chondroitin or chondroitin sulfate per day, alternatively at least about 0.3 g chondroitin or chondroitin sulfate per day; alternatively between about 0.1 g and about 2.0 g chondroitin or chondroitin sulfate per day, alternatively between about 0.1 and about 1.5 g chondroitin or chondroitin sulfate per day, alternatively between about 0.2 g and about 2.0 g chondroitin or chondroitin sulfate per day, alternatively between about 0.2 and about 1.5 g chondroitin or chondroitin sulfate per day, alternatively between about 0.3 g and about 2.0 g chondroitin or chondroitin sulfate per day, alternatively between about 0.3 and about 1.5 g chondroitin or chondroitin sulfate per day.

137. Chondroitin and betaine for use according to any one of claims 86 to 136, wherein the betaine is administered in an amount of at least about 0.8 mg per day, alternatively at least about 1 mg of betaine per day, alternatively at least about 1.2 mg of betaine per day, alternatively at least about 1.4 mg of betaine per day, alternatively between about 0.8 mg and about 28 mg of betaine per day, alternatively between about 0.8 mg and about 25 mg of betaine per day, alternatively between about 0.8 mg and about 21 mg of betaine per day, alternatively between about 0.8 mg and about 17 mg of betaine per day. alternatively between about 1 mg and about 28 mg of betaine per day, alternatively between about 1 mg and about 25 mg of betaine per day, alternatively between about 1 mg and about 21 mg of betaine per day, alternatively between about 1.2 mg and about 17 mg of betaine per day. alternatively between about 1.2 mg and about 28 mg of betaine per day, alternatively between about 1.2 mg and about 25 mg of betaine per day, alternatively between about 1.2 mg and about 21 mg of betaine per day, alternatively between about 1.2 mg and about 17 mg of betaine per day.

138. Chondroitin and betaine for use according to any one of claims 86 to 137, wherein the chondroitin is administered in an amount of at least 0.1 g chondroitin or chondroitin sulfate perAttorney Docket No. 16003WOO1day, optionally between 0.1 and 1.5 g chondroitin or chondroitin sulfate per day, and the betaine is administered in an amount of at least 1 mg of betaine per day, optionally between 1 and 20 mg of betaine per day.